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About 40 million people worldwide have been infected with the human 
immunodeficiency virus (HIV) (UNAIDS/WHO, 2004). Sub-Saharan Africa remains 
the most severely affected region in the world with 25.4 million people living with 
HIV at the end of 2004. In South Africa, the estimate of HIV-1 prevalence from the 
national population-based survey in adults aged 15-49 years was about 16% [Shisana 
et al., 2002). A study conducted by the Medical Research Council (2004) revealed 
HIV prevalence of37.5% among pregnant women in KwaZulu-Natal. An estimated 
5.3 million people were infected with HIV at the end of 2003 in South Africa HIV 
infection affects multiple organs and the kidney is a common target. Black patients 
have a relative risk of 51.1 for developing end-stage renal disease (ESRD) from AlDS 
or an AIDS-defining diagnosis compared with white patients [Barisoni, 2003]. HIV­
associated nephropathy (HIV AN) is reported as the commonest form of chronic renal 
disease in HIV infected patients and is the third leading cause of ESRD in African 
Americans aged 20 to 64 in the United States [D' Agati et al., 1997; Monahan et al., 
2001; US RDS, 2001 ]. The prevalence ofrenal diseases associated with HIV infection 
in Africa and South Africa is unknown. There is a lack of surveillance and reporting 
for renal disease in HIV positive patients. Therefore, in order to assess the pattern of 
renal disease among the HIV- infected South African patients, this study was 
performed. 
Early detection of HIV AN may be beneficial in evaluating early treatment in an 
attempt to protect the kidney from further disease progression. This study, therefore, 
also attempts to diagnose mv AN at an early stage. 
xvu 
This is a single center, prospective cohort study. Six hundred and fifteen patients 
attending the HIV clinic and in-patients from King Edward VIII hospital were 
screened. Inclusion criteria were HIV seropositivity, proteinuria ranging from 
persistent rnicroalburninuria to overt proteinuria. Patients with two positive tests for 
rnicroalburninuria at least a month apart were selected as having persistent 
rnicroalburninuria . Exclusion criteria were diabetes mellitus, uncontrolled 
hypertension, known causes of chronic kidney disease and serum creatinine 
>250µmol/l(i.e to select those patients with early nephropathy). A total of 30 patients
(29 blacks; 1 mixed race) were recruited and followed up between April 2002 and 
September 2004. All patients underwent percutaneous renal biopsy. CD4 counts, urea 
and electrolytes, serum creatinine, creatinine clearance (Cr Cl), 24 hour urinary 
protein were done at the study entry and 3-6 monthly thereafter. ANF ( anti-nuclear 
factor ), WR (Wasserman reaction), Hepatitis Band C were also done. Patients in this 
study were not on anti-retro viral therapy. None of them had used heroin or any illicit 
drugs in the past. 
Total of 11 patients with proteinuria <1 gm/24hours were randomised to receive either 
Perindopril (6 patients) or no treatment (5 patients, as control). All 19 patients with 
proteinuria > 1 gm/24hours were put on Perindopril. HIV AN was found in 25 (86.2%) 
patients with a mean CD4 count of232 (3 - 586 ). Of these 25 patients, 6( 24%) had 
microalbuminuria. Altogether, 7 patients with persistent microalbuminuria were 
biopsied and 6 (85.7%) showed HIV AN with a mean CD4 count of216/mm3 and 
mean creatinine clearance of 132 ml/min. Other biopsy findings included: 
membranoproliferative nephropathy in 2 (7%)and interstitial nephritis in 3 (10%). 
Four patients with HIV AN had associated membranous nephropathy. In patients with 
proteinuria <!gm/day, ACE inhibition leads to abrogation of proteinuria, whereas it 
XVlll 
was non-significantly worsened in controls (p=0.357). Serum creatinine and Cr Cl 
improved non-significantly with ACE therapy (p=0.3327 and 0.405 respectively), but 
significantly worsened in the control group (p= 0.047 and 0.042 respectively). 
Patients with proteinuria > 1 gm/day on ACEI therapy had a significant reduction in 
proteinuria (p=0.003); in addition, renal function was preserved. When the 2 
treatment groups were compared, no deterioration of Se Cr, Cr Cl and proteinuria 
was found in patients with protinuria of <l  gm/day, whereas improvement trends of Se 
Cr and Cr Cl with significant reduction of proteinuria (p= 0.006) was noticed in the 
> 1 gm/day group. The effect of ACEI therapy in delaying disease progression was
assessed by comparing the percentage of patients whose Cr Cl had halved at the end 
of study. No patients from the group with proteinuria of < 1 gm/24 hr on ACEI 
therapy had their Cr Cl halved, whereas 1 out of 5 (20%) patients from the control 
group had Cr Cl halved at the end of the study. From the> I gm/day group, 2 out of 19 
(10.5%) patients showed halving of Cr Cl , implying the renoprotective effect of 
ACEI with better protection when commenced at the early stage of proteinuria. 
In conclusion, HIV AN is the commonest renal biopsy finding amongst our study 
patients with HIV infection. ACE inhibition was found to be effective in early renal 
disease associated with HIV infection, presenting with any degree of proteinuria. 
Microalburninuria is a manifestation of HIV AN in our study patients. Most patients 
with HIV AN had low CD4 counts (<250/mm3). Screening for persistent 
microalbuminuria may be beneficial in HIV-infected patients with low CD4 count. 
Renal biopsy may be a consideration in those with persistent microalbuminuria, in 
order to diagnose HIV AN at an early stage to achieve the maximum benefits of ACE 
inhibition. Further prospective randomised controlled trials of ACEI and ARV 





1.1 Global impact of HIV/AIDS 
Sixteen thousand persons are estimated to be newly infected with the Human 
immunodeficiency virus (HIV) each day worldwide; among them, more than 40% are 
women, more than 50% are 15- to 24-year-olds, and 10% are children age 14 years or 
younger. About 40 million people worldwide have been infected with HIV (Figure 1 ). 
Sub-Saharan Afiica remains the worse affected region in the world with 25.4 million 
people living with HIV at the end of2004[UNAIDS/WHO,2004] (Figure 2). Just 
under two thirds (64%) of all people infected with HIV are in sub-Saharan Afiica, as 
are more than three quarters (76%) of all women living with HIV. In this region, HIV 
seroprevalence rates have been among the highest; for example serologic surveys 
conducted among pregnant women in Botswana, Uganda, Zambia, Malawi and South 
Afiica have found infection rates of20% to 35% in urban areas and about 10% in 
rural areas [US. Bureau of the Census, 1995 & 1998]. HIV seropositivity has been 
found in 7.4% of the population aged 15 - 49 years [Sande and Volberding, 1999]. In 
South Afiica, an estimated 5.3 million people were infected with HIV end-2003 
[UNAIDS, 2004]. The estimate ofHIV-1 prevalence from the national population­
based survey in adults aged 15-49 years was about 16% [Shisana et al., 2002]. A 
study conducted by Medical Research Council revealed an increasing prevalence
among pregnant women aged 15-24 years, from 23.1% in 2001 to 24.3% in 2003 
(Figure 3), with the highest prevalence in KwaZulu-Natal (37.5%) [UNAIDS/WHO, 
2004]. 
HIV is now the number one killer worldwide amongst other infectious agents 
[Idemyor, 2003]. About 12 million people have died from AIDS over the last 20 years 
[Thaker et al., 2003]. In South Afiica, number of deaths due to HIV related illnesses 
is increasing every year, with nearly half a million people dying in 2003 (Figure 4). 
The IIlV epidemic, therefore, has had a huge global impact, with sub-Saharan Africa 
being the major target of this deadly disease. 























( UNAJDSIWHO,AJDS epidemic update: December 2004 ) 
Figure 2. 
HIV prevalence among 15-49 year-old men and women, 
in urban and rural areas, in selected 
sub-Saharan African countries, 2001-2003 
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1.2 Characteristics of HIV 
HIV- I is a member of the Lentivirinae subfamily of retroviruses. Other lentiviruses 
include the simian immunodeficiency virus (SIV), which causes an AIDS-like disease 
in Asian monkeys; the visna and maedi viruses, which cause severe demyelinating 
encephalomyelitis and interstitial pneumonia in sheep; the caprine arthritis­
encephalitis virus; the equine infectious anaemia virus; and the feline 
immunodeficiency virus. 
The remarkable feature of the lentiviruses, which differs from other retroviruses, is 
the complexity of their viral genomes (Figure 5). Most replication-competent 
retroviruses contain only three genes, gag, pol, and env. The gag and env genes 
encode the inner core polypeptides and envelope proteins of the virus, respectively, 
whereas the pol gene gives rise to the viral reverse transcriptase, integrase, and 
protease activities. However, IDV-1 contains within its 9-kilobase pair (kb) RNA 
genome not only these three essential genes but at least six additional genes ( vif, vpu, 
vpr, tat, rev, and nef). The proviral DNA is flanked by long terminal repeats (LTRs), 
which are important for both transcriptional regulation and polyadenylation [ Sande
and Volberding, 1999]. 
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Figure 5. Genomic structure of IIlV -1 
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The IIlVI- virion contains an inner conical structure and 72 external spikes formed by 
the two major viral envelope proteins, gp 120 and gp41. The IIlV-1 lipid bilayer is 
also studded with a number of host proteins, including class I and class II major 
histocompatibilty complex (MHC) antigens, acquired during virion budding. The viral 
core contains four proteins: the p24 capsid protein, the p 17 matrix protein, and the p7 
and p6 nucleocapsid proteins, each of which is proteolytically cleaved from a 55-kDa 
Gag precursor by the IIlV-1 protease. The capsid protein forms the chief component 
of the inner shell of the virion, whereas the myristylated matrix protein is associated 
with the inner surface of the lipid bilayer and probably stabilizes the exterior and 
interior components of the virion. The p7 nucleocapsid protein binds directly to the 
genomic RNA through a zinc-finger structural motif and together with the p6 
nucleocapsid, forms the retroviral core. This core also contains two copies of the 
single-stranded IIlV-1 genomic RNA that are associated with the various preformed 
viral enzymes, including reverse transcriptase, integrase, and protease (Figure 6). 
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• mv Type 1 {IIlV-1 ), which is responsible for the global pandemic; and
• mv Type 2 (IIlV-2), which is less pathogenic than IDV-1, and largely
restricted to West Africa, with limited spread to other countries [Wilson et al.,
2004].
illV-1 is a highly variable virus. By using nucleotide sequence comparisons, it is 
further classified into three groups: 
• Group M (major) viruses: This group is further divided into 10 phylogenically
related genetic subtypes or clades (A,B,C,D,Fl,F2,G,H,J and K). These
subtypes, together with a growing number of circulating intersubtype
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recombinant forms, comprise the majority of HIV-I variants in the world. 
Subtypes are unevenly distributed around the world with subtypes A, C and D 
being the commonest in Africa and subtype B dominating North America and 
Western Europe. Subtype C, in fact, is emerging as most prevalent, being 
common in India, and the southern African countries of Botswana, Zimbabwe, 
Malawi, Moz.arnbique, and South Africa, where it is estimated to be 
responsible for over 90% of infections. Recombinant viruses, which are 
viruses with mosaic genomes made up of different subtypes, are becoming 
more common in regions where multiple subtypes are circulating. Numerous 
circulating recombinant forms (CRF) have been identified, e.g. CRFOI_AE, 
which is a mixture of subtype A and E; and CRF02 _ AG, which is a mixture of 
subtype A and G. 
• Group O (outlier) viruses: These are largely restricted to the central African
region.
• Group N (non-M; non-OJ viruses: These are rare and have been identified in
only a few individuals in Cameroon.
HIV-I virus is a rapidly evolving virus due to the error-prone nature of reverse 
transcriptase and the high viral turnover. The ability of the virus to adapt rapidly and 
to diversify has the following serious implications: 
• It enables the virus to escape detection by the immune system.
• It enables rapid development of drug resistance.
• It may affect vaccine efficacy.
• It may affect accurate diagnosis, especially pertaining to assays based on
detection of the virus, such as a viral load assay.
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1.4 Laboratory Testing for HIV-1 
Since its discovery in 1984, the presence oflllV-1 infection is tested by direct or 
indirect methods, detecting virus itself or viral antibodies respectively [Grant et al., 
1999; Sandler et al., 1988] 
1.4.1 HIV Antibody Tests 
There are two tests available to detect viral antibodies. 
1.4.1.1 Standard Enzyme-linked immunosorbent assay (ELISA) 
This test has been used widely from 1985, based on the technology to perform ELISA 
available in earlier years. Patient's serum is added to a microwell plate coated with 
antigens derived from an IDV-1 tissue culture lysate. Bound anti-IDV antibody from 
the infected patient is detected via a goat anti-human antibody labeled with an enzyme 
designed to react with a specific substrate. The cleaved substrate product yields a 
colour that can be measured photometrically; but this test may yield false positive 
results due to the presence of cross-reacting antibodies, such as those against class Il 
human leukocyte antigens (IIl.,A-DR-4 and DQw-3). These antibodies are frequently 
present in multiparous women and persons who had received blood transfusions. 
Other autoantibodies such as parietal cells or smooth muscle antibodies, antinuclear 
antibodies, antimitochodrial antibodies and anti-T-cell antibodies also can lead to 
false-positive results. False-negative results can also occur during the seronegative 
window period of 1 to 3 months (i.e between the time of initial infection and the 
development of a detectable immune response). Other causes of false-negative 
reactions include replacement transfusions, bone marrow transplantation, and 
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commercially available test kits that detect antibody to p24 only (e.g the ELISA test 
using recombinant p24 antigen). However, a positive ELISA test result should be 
classified as " HIV reactive" not positive, and should be confirmed by a supplemental 
test such as Western blot. 
1.4.1.2 Western Blot (WB) 
This is the most commonly used supplemental test. It is performed by separating 
tissue culture-derived HIV-1 proteins and glycoproteins via polyacrylamide gel 
electrophoresis, transferring (blotting) the separated proteins onto nitrocellulose 
paper, incubating the cut strips of nitrocellulose paper with patient serum, and 
detecting anti-HIV antibodies that have bound to the HIV-associated proteins at the 
precise point at which they migrated in the gel. Through this procedure, the antibody 
reactivity against specific antigens can be detennined. Antibodies can be identified to 
six major HIV proteins: gp 41 and gp 120 (envelope), p24 and pl 7 (core), and p66 
and p3 l ( reverse transcriptase ). Western blot (WB) test result, however, can be non­
specific and indeterminate. Therefore, several organiz.ations such as the World Health 
Organization (WHO) and the Centres for Disease Control and Prevention (CDC) have 
proposed criteria for interpreting Western blot reactivity. The two most commonly 
used criteria recommend that reactivity to (1) p24 and gp41 or gpl20/160 or (2) p24 
or p3 l and gp4 l or gp I 20/ l 60 be observed to diagnose IDV-1 positivity 
Approximately 15 to 300/o of ELISA-negative samples produce indeterminate results 
on WB. Among ELISA-reactive samples, 4 to 20% can show indeterminate WB 
results [Kleinman et al., 1990; Genesca et al., 1989]. 
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1.4.1.3 Radioimmunoprecipitation Assay (RIPA) 
This test requires ongoing HIV-I replication in lymphocytic cell lines which occurs 
in the presence of radiolabelled amino acids which are then incorporated into viral 
proteins. A cell lysate is then prepared and is incubated with patient serum. Anti-HIV-
1 antibodies present in the serum react with the radiolabelled antigens and fonn 
immune complexes, which are removed by incubating the reaction mixture with 
protein A-coated beads. These beads bind the Fe portion of immunoglobin molecules 
and are separated from the reaction mixture through centrifugation. By adding a 
detergent, antibody-antigen complexes are eluted from the separated beads. The 
immunoprecipitants are then run through an electrophoretic gel, which separates them 
according to their molecular weight as in the Western blot method. An 
audioradiograph of the gel provides a banding pattern which is very similar to that of 
the Western blot test. 
This assay is considered more sensitive and specific than the Western blot test. 
However, it is more expensive, time consuming and labour-intensive, because of 
which it is usually reserved for difficult-to-diagnose cases. 
1.4.1.4 Indirect Immunofluorescence Assay (IFA) 
The indirect immunofluorescence assay (IF A) requires preparation of IIlV-1 antigens 
that are expressed on infected cells, similar to RIP A. Infected cells are placed on glass 
slides in a fixed monolayer and are then incubated with patient serum which contains 
anti-HIV- I antibodies. These antibodies bind to antigens which are expressed on the 
surface of infected cells. Bound antibodies are then detected with anti-human 
antibody that has been labelled with fluorescein isothiocyanate (FITC). After further 
necessary processing, the slide is examined under a fluorescent microscope, and the 
number of cells, the intensity and pattern of staining are assessed. IF A can detect the 
earliest serologic response against the virus, which is the formation of 
immunoglobulin M (lgM) antibodies, during acute infection. However, due to time, 
expense, and expertise required for this test, it is impractical to be used routinely. 
1.4.1.5 Other Anti-HIV-1 Antibody Tests 
Double antigen-capture ELISA tests: These are the third generation of standard 
anti-IDV ELISA with increased sensitivity which are based on using labelled IDV-1 
antigen to detect binding of patients antibodies to beads also covered by lilV - I 
antigens. Therefore, these assays detect all classes of antibodies including IgM that 
form during acute infection. These are more sensitive assays allowing earlier 
detection of 1-IlV -1 seroconversion. 
Detuned ELISA: This is the assay that is intentionally modified to become less 
sensitive. It involves modification of the sample dilution and sample incubation time. 
This assay allows detection of recent HIV-1 seroconversion from a single serum 
sample. 
Antibody test using recombinant purified HIV-1 antigens: These recombinant 
antigens replace viral lysates which contain substantial amounts of host cell antigens 
that may cross-react with the patient's serum and yield false-positive results. 
Recombinant virus proteins are more pure, therefore, other serum reactions with host 
cell are eliminated, and provide increased specificity. 
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Rapid antibody test: These tests are done by using filter paper embedded with HIV­
I antigens. The serum to be tested is passed through the filter paper. After a wash, the 
secondary antibodies are passed over the filter, allowing binding to anti-HIV 
antibodies that were retained. These rapid tests are easier to perform and are designed 
to be done one at a time eliminating the need for batch testing. However, these test 
results need to be confirmed by using confirmatory tests such as p24 antigen assays. 
1.4.2 Viral Culture Techniques 
There are various culture techniques to isolate the HIV- I virus. 
1.4.2.1 Peripheral Blood Mononuclear Cell Co-culture for HIV-1 isolation: 
Viable peripheral blood mononuclear cells (PBMCs) from HIV-I-infected patients are 
collected by centrifugation of anticoagulated whole blood, which are then co-cultured 
with PBMCs from uninfected human donor that have been stimulated previously. Cell 
growth in tissue culture is supported by a special medium to stimulate expression of 
CR4 receptors for enhanced viral replication and proliferation of lymphocytes. The 
cultures are observed for syncytium formation (i.e multinucleated giant cell 
formation) as evidence of viral infection in vitro, and for the presence of either HIV- I 
reverse transcriptase (RT) activity or HIV-I p24 antigen production in the culture 
supernatant. When performed properly, this culture technique is positive in 95% to 
990/4 of HIV- I infected patients. 
1.4.2.2 Quantitative Cell Culture: This technique measures the relative amount of 
viral load within cells. The culture technique is the same as the previous method 
however, decreasing amounts of patient's cells are used to co-culture with fixed 
amount of donor cells. In this way, fewer patient's cells are introduced into the co­
culture system, thereby allowing measurement of relative viral burden. 
1.4.2.3 Quantitative Plasma Culture: This is the measurement of free infectious 
virus in the plasma. This is done through quantitative plasma culture techniques. 
Serial dilutions of plasma are prepared and mixed with PBMCs from uninfected 
donor. To ensure accuracy, these tests are done in duplicate or quadruplicate. 
1.4.2.4 Ultrasensitive Cell Culture: This method provides the optimal culture 
condition for tissue reservoirs ( such as resting memory CD4+ T lymphocytes) for 
HIV-I . By doing so, it increases the sensitivity of the standard method, thereby 
allowing HIV-I to be cultured from nearly 100% of subjects with suppressed IIlV-1 
RNA. This test, therefore, can be used in patients who are on antiretroviral therapy. 
However, the clinical utility of these ultrasensitive cultures remains unclear. A wider 
range of tests needs to be done to get reproducible results. 
1.4.3 P24 Antigen Assays 
1.4.3.1 HIV p24 Antigen test 
This is an ELISA-based test that detects the presence of free IIlV-1 np24 antigen in 
the patient's serum. Free antigen is bound (captured) by specific anti-p24 capture 
antibodies coated onto a microwell. Bound antigen is detected by specially designed 
rabbit anti-IIlV P24 (detection antibodies), which in turn, are detected by goat anti­
rabbit antibodies. The goat antibodies have been conjugated with an enzyme that 
cleaves a specific substrate, yielding a coloured product. By photometrically 
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measuring the degree of colour in the well, the amount of l-llV-1 p24 antigen can be 
determined quantitatively. This test can identify p24 antigen before 1-llV antibodies 
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are detectable in more than 90% of subjects [Gallarda et al., 1992]. More recently, the 
use of monoclonal anti-p24 antibodies has increased the sensitivity of the assay 
significantly, allowing p24 antigen levels as low as 7 to IO pg/ml to be detected 
reliably. 
1.4.3.2 Acidified p24 Antigen Procedure 
This is a modified p24 antigen test which increases the sensitivity of this test. This 
modification is based on the concept that in the presence of significant amounts of 
anti-p24 antibody, p24 antigen forms antigen-antibody complexes thereby preventing 
detection of free antigen. Through acidification of plasma, these complexes are 
disrupted, releasing free antigen for detection by the antigen assay. This technique 
may be useful in observation of patient responses to antiretroviral therapy, although 
more recent data indicate that regular p24 antigen testing may be more informative. 
1.4.4 Quantitative Viral RNA and DNA Assays 
These assays are used to measure the viral load and are based on the Polymerase 
Chain Reaction (PCR), Branched-Chain DNA (bDNA) and Nucleic Acid Sequence­
Based Amplication (NASBA) techniques. mv RNA and DNA can be detected in 
almost all lilV -infected patients before 1-llV antibodies become detectable. 
All of the currently available viral load assays have false positive rates ofup to 5%, 
although the mechanism underlying false-positive test results differs between assays. 
In practice, the specificity of viral load assays for diagnosing HIV-I infection is 
typically between 95% and 990/o, which is considerably worse than the specificity of 
p24 antigen assays and antibody assays, 
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Therefore, HIV-I antibody assays remain the gold standard for the diagnosis of HIV­
I infection. 
1.5 HIV and Renal Disease 
HIV infection affects multiple organs and the kidney is a common target. 
The association between HIV and renal disease was first reported in 1984 by 
investigators in New York City and Miami [Rao et al., 1984; Pardo et al., 1984]. They 
reported a series of HIV-I seropositive patients who developed a renal syndrome 
characterised by proteinuria and progressive renal failure. 
A variety of renal syndromes can occur during the course of HIV infection. These 
can be divided into disturbances of fluid-electrolyte and acid-base metabolism, acute 
renal failure, immune-mediated glomerulopathies and chronic progressive renal 
failure. 
1.5.1 Fluid-electrolyte and acid-base disturbances 
Sodium 
Hyponatraernia is the commonest electrolyte disturbance in patients with HIV 
infection. In hospitalized patients, it was observed in 30% to 56% of persons with 
AIDS or AIDS-related complex (ARC), as compared with I% incidence in general 
medical-surgical inpatients[Anderson RJ, 1986]. In a prospective analysis by Tang et 
17 
al, hyponatraemic patients were hospitalized for 17 ± 1 days, with a mortality rate of 
36. 5%, significantly higher than the 9 ± 1 hospital days and 19. 7% mortality rate in
the normonatraemic group [Tang et al., 1993] There are many causes that lead to low 
serum sodium which include vomiting, diarrhoea, reduced intake, insensible losses 
due to fever or respiratory diseases. The other causes are syndrome of inappropriate 
antidiuretic hormone secretion (SIADH) secondary to pulmonary and central nervous 
system lesions and adrenal insufficiency. Nephrotoxic drugs such as Amphotericin 
can induce renal sodium loss. 
Hypematraemia occurs less commonly in IDV-infected patients. In a survey of 100 
hospitalized AIDS patients, the prevalence of hypernatraemic dehydration (serum 
sodium > 149) was less than 5% [Rao TKS, 1998]. Causes include volume depletion 
and acquired nephrogenic diabetes insipidus secondary to drugs such as Amphotericin 
and F oscarnet. 
Potassium 
Hypokalaemia can be found in 17% of patients with AIDS [ Peter SA, 1991] in the 
setting of volume depletion such as gastro-intestinal (GI) loss from diarrhoea or in the 
presence of metabolic alkalosis or drug induced tubular acidosis due to Amphotericin 
B, Rifampin and Co-trimoxazole. It can also be a complication ofFanconi syndrome 
associated with the antiretroviral drug, Adefovir. 
Hyperkalaemia has been reported in 16 to 21 % of hospitalised AIDS patients. Causes 
are not different from seronegative patients such as renal failure, acidosis and adrenal 
insufficiency. Drugs commonly used in treating opportunistic infections such as 
Trimethoprim and Pentamidine are also known to be associated with hyperkalaemia. 
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Calcium 
Deranged serum calcium levels are frequently observed among the lilV positive 
patients. About 18% and 3% of hospitalised AIDS patients develop hypo- and hyper­
calcaemia respectively. HypocaJcaemia occurs due to hypoalbuminaemia and 
medications such as Foscamet, Pentamidine and Didanosine. Increased serum calcium 
levels are seen in patients with disseminated CMV infection and in those with 
granulomatous disease. 
Magnesium 
Hypomagnesaemia as a result of renal magnesium wasting can be seen in patients 
treated with both Pentamidine and Amphotericin. 
Uric acid 
Hypouricaemia is observed in 22% of patients with ARC and AIDS [ Maesaka et al., 
1990], compared to 1% of those admitted for other reasons. It is more common in 
women and intravenous drug abusers. It results from a defective renal handling of uric 
acid. 
Hyperuricaemia can be found in IDV-infected patients either secondary to 
dehydration or malignancies. It is also commonly seen with ddl therapy because of its 
metabolism to hypoxanthine and subsequently to uric acid. Tubular urate deposits 




Acute or chronic gastroenteritis occurs commonly in IDV-infected patients, resulting 
in bicarbonate losses in the stool causing non-anion gap metabolic acidosis. Lactic 
acidosis can be seen in the setting of sepsis or severe hypoxaemia due to 
overwhelming respiratory tract infection. Lactic acidosis, not associated with hypoxia 
or hypoperfusion, known as type B lactic acidosis has been reported in some patients 
with AIDS. 
Respiratory alkalosis can occur due to hyperventilation induced by pulmonary 
infections. When lungs decompensate or respiratory muscle fatigue occurs late in the 
course of infection, respiratory acidosis may be a complication. 
Fanconi syndrome 
Some of the antiviral drugs like Cidofovir and Adenovir have nephrotoxic effects 
which can cause F anconi syndrome, manifested by proximal renal tubular acidosis 
with bicarbonate wasting, hypophosphataemia, glycosuria, aminoaciduria and 
hypokalaemia. This usually resolves with discontinuation of the drug. 
1.5.2 Acute renal failure 
Acute renal failure (ARF) is a common complication in patients with AIDS. Valeri et
al ( 1991) studied 449 hospitalized AIDS patients and ARF (defined as 2mg/dl [ 176.8 
µmol/1] or greater increase in baseline serum creatinine concentration ) was found in 
88 (20%,) patients . Other reports indicated that the incidence of ARF was 6% to 20% 
in hospitalized AIDS patients [Rao TKS, 1998]. 
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The aetiology of acute renal failure in AIDS patients is not different from those found 
in patients without AIDS. The causes can be categorized into pre-renal, intrinsic renal 
and post-renal [Rao TKS, 1998]). Table I illustrates the various causes of ARF in 
HIV-infected patients. ARF is attributed to ischaemic renal injury secondary to sepsis 
in about 50%, to nephrotoxic agents such as aminoglycosides, amphotericin, and 
intravenous radiocontrast agents in about 25%, and to other causes including acute 
interstitial nephritis, rhabdomyolysis, massive gastrointestinal bleeding, hepatic and 
cardiac failure in the remaining 25% [Monahan et al., 2001]. 
Table 1 . Acute Renal Failure in HIV disease 
Pre-renal. 
• Hypovolaemia ( diarrhoea, vomiting, CNS infections/tumors)
• Hypotensioo ( sepsis, bleeding, fluid loss)
• Hypoalbuminaemia (massive proteinuria, cachexia, third space fluid loss)
Renal. 
• Acute tubular (hypovolaemia, shock, sepsis, anoxia, and nephrotoxin)
• Rhabdomyolysis (pentamidine, zidovudine, HIV, cocaine)
• Acute azotaemia from nonsteroidal anti-inflammatory drugs
• Allergic interstitial nephritis (trimethoprim-sulfamethoxazole, phenytoin,
rifampin, others)
• Plasmacytic interstitial nephritis
• ARF from haemolytic uraemic syndrome
• ARF from thrombotic thrombocytopaenic purpura
• Postinfectious immune complex glomerulonephritis, other glomerulopathies 
• Renal oedema from massive proteinuria and severe hypoalbuminaemia
• Multiple myeloma
Post-renal. 
• lntrarenal tubular obstruction ( crystal
• Extrinsic ureteral compression (lymph nodes, tumours) induced from
sulfadiazine, acyclovir, prote.ase inhibitors, and tumour lysis syndrome)
• Retroperitoneal fibrosis
• Intrinsic ureteral obstruction (fungal balls, blood clots)
• Bladder and urethral obstruction
[Rao TKS, 1998] 
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Pre-renal 
Pre-renal azotaemia is most often secondary to volume depletion from gastrointestinal 
losses due to diarrhoea and vomiting, dehydration from poor intake due to CNS 
involvement, and hypotension resulting from septicaemia. Occasionally, intravascular 
volume depletion can occur due to sequestration of fluid into third space in patients 
with hypoalbuminaemia as a result of massive proteinuria, chronic diarrhoea or severe 
malnutrition. 
Renal 
Among the intrinsic renal causes, acute tubular necrosis (ATN) is the most common 
form of acute renal failure. In autopsy series, the prevalence of A TN in AIDS varied 
between 8% and 300/4, but the actual percentage may be higher because renal biopsy 
was rarely performed in patients with azotaemia [Rao TKS, 1998].However, in recent 
years, the incidence of severe ATN is decreasing [ Rao TKS et al., 1995], due to the 
overall improvement in the management of AIDS patients. Both oliguric and non­
oliguric forms of A TN are common in AIDS patients. The clinical course is variable, 
ranging from a mild, short duration of oliguria and azotaemia which is self-limited to 
that of life-threatening uraemia, requiring intensive care management with dialysis 
and other life support. 
Acute interstitial nephritis is also seen in the IDV-infected patients [Monahan et al., 
2001]. It may be due to infection or due to hypersensitivity drug reaction from various 
medications. Infectious agents include candida, tuberculosis, cytomegalovirus and 
histoplasmosis. Medications frequently used in treating IDV-infected patients with 
associated diseases and disorders are also responsible for acute interstitial nephritis, 
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which include peoicillin, oepbalosporins, ciproffoxacin. trimethoprim 
suJphamethoxawle, phmytoin, rifiunpieio and noosteroidal anti-ioftammato drugs. 
A rare form of ARF in HIV-infected patients, which is a tmltable cooditioo is 
pJasmacytic interstitial nephritis (PIN). Patients present with either mi1d to nephrotic 
range proteinuria and az.otaemia. Diagnosis is confinned by renal biopsy wbicll shows 
normal glomeruli with plasma cell infiltration in the inte,stitinm It responds well to 
corticosteroid therapy [Hom et al., 1989]. 
Post-renal 
Post-renal causes of AltF are also common in IHV-infected patiems. Clystal 
deposition in the kidney tubules causing-Obstructive nephropathy has been seal in 
seropositive patients receiving medications such as sadtiwtiazine, intravenous 
acyclovir, indinavir aod foscamet {Monahan et al., 200 l]. Asymptomatic aystalluria 
can occur in up to W-/4 of patients who are on lndinavir tbaapy. Approximately S-/4 
show symptoms of dysuria and renal colic with mild renal insrdficiency. Most 
patients improve with adequate fluid replacement and discotdittiation of the drug_ 
Renal tubular obstruction due to 1.B'11te deposition has been described in patients with 
AIDS--associated lymphoma who were treated with chemotherapy, resulting in 
hyperuricosuria ftom tumour fysis syndrome [Ogea Garcia et al., 1989}. 
In summary, AltF syndromes OCaJr oommooly in IHV-mfected patients in protean 
ways. It is important to look for the causes which are potentially treatable With early 
diagnosis and neru,ary measures, inducting dialysis and other- life supports offeaed 
appropriately, can improve the outcome of the patients. 
1.5.3 HIV-associated immune complex renal disease (HIVICD) 
There are three distinct HIV-associated glomerulonephritides: 
• Proliferative glomerulonephritis
• Mixed sclerotic-immune complex nephropathy
• IgA nephropathy [Kimmel et al., 1995; Nochy et al., 1993]
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mvICD occurs much less frequently than HIV AN, although some biopsy series from 
the United States done in patients presenting with renal impairment, acute renal 
failure or nephritic syndrome have demonstrated proportions as high as 25% to 33% 
[Glassock et al., 1990; Kimmel et al., 1993, 1994, 1995; Nochy et al., 1993; Guerra et 
al., 1987; D' Agati et al., 1997 ]. European and Asian case series of HIV-infected 
patients with renal disease who underwent renal biopsies or autopsies show that 
patients of European descent typically have glomerulonephritis, however, patients of 
African descent in the same center usually have HIV AN [Hailemariam et al., 2001; 
Nochy et al., 1993, Casanova et al., 1995; Connolly et al., 1995; Praditpomsilpa et 
al., 1999; Williams et al., 1998; Kimmel et al., 1995]. This difference in the pattern of 
renal diseases among the different racial groups suggest a critical role of host or 
genetic factors in the phenotypic presentation of renal disease in HIV-infected 
patients. 
Disease such as membranoproliferative glomerulonephritis, membranous 
nephropathy, and postinfectious glomerulonephritis are often seen in the presence of 
hepatitis B and/or hepatitis C viral infection. These infections are found to be 
common in HIV-infected patients with renal disease, especially among intravenous 
drug users. However, the underlying pathogenesis remains unclear [Weiner et al., 
2003]. 
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IgA nephropathy also occurs in HIV-infected pateints [Kimmel et al., 1992, 1995, 
2000; Katz et al., 1992], however, its incidence and prevalence are unknown. In an 
autopsy study, diffuse mesangial deposits were found in 7. 75% of AIDS patients 
[Beaufils et al., 1995]. IgA nephropathy in association with HIV infection seems to be 
relatively common in patients of European descent, but uncommon in those of 
African descent [Weiner et al., 2003; Kimmel et al., 1995; Beaufils et al., 1995], as in 
HIV uninfected populations [Donadio et al., 2002]. 
Kimmel et al proposed two potential pathophysiologic mechanisms ofHIVICD: (1) 
deposition of immune complexes acting as the inciting factor; or (2) in situ immune 
complex formation initiated by the presence of the HIV genome in renal tissue 
[Kimmel et al., 1993]. Figure 7 depicts the possible pathophysiologic mechanisms. 
Primary HIV- I infection in patients who are genetically susceptible leads to synthesis 
ofHIV-1 proteins. HIV-I directly infects renal cells and HIV proteins and peptides 
may stimulate local cellular immune responses. Alternatively, circulating 
immunoglobulins (lgM,IgG and lgA) may react with HIV-1 proteins resulting in 
formation of circulating immune complexes, which deposit in renal tissue. A cellular 
immune response, potentially influenced by host genetic factors, may lead to 
production of cytokines, growth factors, chemokines, and adhesion molecules. Such a 
response may lead to various combinations of inflammatory, sclerotic/fibrotic, and 
apoptotic responses. [Weiner et al., 2003] 
The clinical presentation ofHIVICD may be quite different from that of HIV AN. 
Patients with IgA nephropathy present with proteinuria and haernaturia, however, 
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often not with nephrotic range proteinuria [Kimmel et al., 1993]. They tend to have a 
much more indolent course than those with IDV AN and are less likely to progress to 
ESRD [Weiner et al., 2003]. 
Fig. 7. Human immunodeficiency virus-associated immune complex-mediated 
renal disease (HIVICD) 
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1.5.4 HIV-associated thrombotic microangiopathy (HIV-TTP/HUS) 
There has been an increasing number of reports in the literature ofTTP/HUS in lflV­
infected patients over the last few years [Sutor et al., 1999; De Man et al., 1997; 
Jokela et al., 1987; Ucar et al., 1994; Badesha et al., 1996; Hymes et al., 1997; Berns 
et al., 1995; Alpers et al., 2003]. TTP/HUS is characterized by microangiopathic 
haemolytic anaemia and renal insufficiency together with other features such as 
thrombocytopaenia, fever, and neurological changes. The prevalence oflflV infection 
among patients with TTP/HUS varies greatly, ranging up to 36% [Berns et al., 1995]. 
A recent biopsy based retrospective study from France by Peraldi et al (1999) 
suggested the possibility of a higher prevalence oflflV-TTP/HUS than was 
previously considered. TTP has less severe renal failure and anaemia, and 
thrombocytopaenia is most prominent. In contrast, microangiopathic haemolytic 
anaemia predominates in HUS, and renal insufficiency may be extensive [Berns et al., 
1995]. However, it may be difficult to differentiate these two entities. The 
pathogenesis of lflV-TTP /HUS is unknown. In uninfected patients, various aetiologic 
factors have been identified such as bacterial infections ( especially Escherichia coli), 
drugs such as cyclosporin, mitomycin, and bleomycin; and concomittent illnesses 
such as malignancies, systemic lupus erythematosus and scleroderma [Berns et al., 
1995]. However, the contribution of such factors to the pathogenesis oflflV­
TTP/HUS is unclear. mv peptides such as p24 may play a role in the pathogenesis, 
perhaps because of their cytopathic effect or as a result of changes following the 
infection of endothelial cells [Del Aero et al., 1993]. 
The clinical manifestations oflflV-TTP/HUS is similar to the idiopathic forms of the 
disease, although the demographics differ [Weiner et al., 2003]. IDV-TTP/HUS 
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occurs mainly in young men, with an 80% male predominance, and a mean age of 
onset of 35 years. [Berns et al., 1995]. It more commonly occurs in Caucasians than 
in Afiican Americans or Hispanics. [Berns et al., 1995]. Renal insufficiency is usually 
mild to moderate. Twenty four hour urinary protein excretion may be in the nephrotic 
range [Charasse et al., 1991; Meisenberg et al., 1988]. However, the prognosis for 
patients with HIV-TTP/HUS is significantly worse than for patients with the 
idiopathic form of the disease, with mortality rates of 66% to 100% [Rao TKS, 2001]. 
1.5.5 Immunotactoid glomerulopathy (ITG) 
ITG is a recognised pathological diagnosis based on renal biopsy specimens since the 
first description more than 2 decades ago [Martin et al., 2003]. To date, there are 
several reports of ITG among the HIV-infected patients, either in association with 
hepatitis C infection or in non-Afiican Americans [Haas et al., 2000; Markowitz et 
al., 1998; Belgiojoso et al., 1996 ] although a case ofITG in a HIV positive but 
hepatitis C-negative African-American has been reported [Martin et al., 2003]. 
The pathogenesis of ITG is unknown. Possible theories include circulating 
immunoglobulins with a propensity for tactoid formation that may be polyclonal in 
nature [Schwartz et al., 2002]. Another recent theory proposes that tactoid formation 
is localized to the podocyte [Schwartz et al., 2002]. If infection of the podocyte from 
the HIV occurs, which has been shown by Winston et al (2001 ), CD2ap, a 80-KD 
protein that normally bind to nephrin in the slit diaphragm of the podocyte is 
disturbed. This may be a possible mechanism for tactoid formation in the podocytes. 
1.5.6 HIV-associated nephropathy (HIV AN) 
1.5.6.1 Definition 
HIV AN is morphologically defined by a collapsing form of focal segmental 
glomerulosclerosis (FSGS), glomerular visceral epithelial cell hypertrophy, and 
prominent tubulointerstitial inflammation with oedema, fibrosis, and rnicrocystic 
tubular dilatation [ D 'Agati et al, 1989; Cohen et al, 1988]. Endothelial 
tubuloreticular inclusions (TRI) were also commonly found in HIV AN biopsy 
specimens before the advent of highly active antiretroviral therapy (HAAR T) 
[D 'Agati et al, 1989]. However, TRI are less commonly found in the post-HAAR T 
era [ D 'Agati et al, 1998 ]. The finding of collapsing FSGS, especially with tubular 
microcystic dilatation in an HIV-1-seropositive patient is almost diagnostic of 
HIV AN. However, renal manifestations in I-llV infected patients can be due to 
conditions other than IBV AN and renal biopsy is required to establish a definitive 
diagnosis, even among the HIV seropositive patients [ D 'Agati et al, 199 7 & 1998]. 
1.5.6.2 Prevalence 
HIV AN is reported as the commonest form of chronic renal disease in HIV infected 
patients and is the third leading cause of end stage renal disease (ESRD) in African 
Americans aged 20 to 64 in the United States [D' Agati et al, 1997; Monahan et al, 
2001; USRDS, 2001]. The true prevalence of HIV AN worldwide, however, is 
unclear. Initial studies suggested that about 10% of HIV infected patients develop 
IIlV AN [Pardo et al, 1984& 1987; Gardenswartz et al, 1984; Rao et al, 1987; 
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Bourgoignie et al, 1988; Valeri et al, 199 lJ. However, it appears that it is influenced 
by the type of study (whether autopsy or biopsy based) and different demographics of 
the HIV infected population, such as racial group. The occurrence of mv AN in 
autopsy studies of AIDS patients varies from 1 to 12% [Mazbar et al, 1990; D 'Agati 
et al, 1989; Seney et al, 1990; Lopes et al, 1992; Shahinian et al, 2000]. Renal biopsy 
series showed a higher prevalence (42 to 64%) than autopsy findings [Connolly et al, 
1995; Winston et al, 1999; Ahuja et al, 1999]. 
Since the introduction ofHAART, the death rate due to AIDS has decreased markedly 
in the United States for all racial groups, including African Americans [CDC, 2001]. 
New cases of ESRD due to HIV AN (reported as AIDS nephropathy by the United 
States Renal Data System) increased rapidly until 1995 and then suddenly began to 
decrease slightly in 1996, possibly reflecting the effect ofHAART [USRDS, 
2001].However, the rate of decline in the incidence ofESRD due to AIDS 
nephropathy has slowed. The number of new cases, in fact, increased in 1999. Ahuja 
et al (1999) screened 557 IDV-l infected patients and reported the prevalence of 
HIV AN to be 1. 79% of all patients and 3. 5% among African Americans� based on 
which, the authors speculated that the incidence of HIV AN may be decreasing. 
In Africa, the incidence and prevalence of renal diseases associated with HIV 
infection including HIV AN is unknown. There is a lack of surveillance and reporting 
for renal disease in HIV positive patients. It is also likely that many Africans with 
AIDS die of opportunistic infections early in the course of disease, before HIV AN 
becomes clinically obvious, as HIV AN is usually a late manifestation of HIV 
infection. However, its occurrence in the early stage of infection has been reported 
[Bourgorgnie et al., 1990; Wmston et al., 1996; D' Agati et al., 1997]. 
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1.5.6.3 Racial Predilection of HIV AN 
The common occurrence of HIV AN among seropositive black and Hispanic patients 
has been reported previously [D' Agati et al, 1997; Soni et al, 1989; Cantor et al, 
1991; Williams et al, 1998]. Based on the data from the United States Renal Data 
System (USRDS), a recent analysis has shown that lllV AN is more strongly 
associated with black race than any other cause of renal failure with the exception of 
sickle cell disease [ Abbott et al, 200 I]. Casanova et al reported a series of 26 renal 
biopsies performed on white Italians, none of whom had IIlV AN. A similar result was 
found among HIV infected Thai patients by Praditpornsilpa et al ( 1999). Winston et 
al (1999) and Ahuja et al (1999), however, reported HIV AN in 50%, and 64% of HIV 
positive African Americans respectively in renal biopsy studies. Hailemariam et al 
(2001) from Switzerland studied 239 autopsies done on AIDS patients between 1981 
and 1989. Different renal abnormalities were found among Caucasian patients; 
however, the only case of HIV AN was detected in one of six black African patients 
included in the study. 
About 25% of patients with HIV AN have first-degree or second-degree family 
members with ESRD, and black patients with HIV AN are 5.4 times more likely to 
have a first-degree or second-degree relative with ESRD than are black patients 
without renal disease [Freedman et al, 1999). 
Some investigators proposed Duffy antigen/receptor for chemokines (DARC) as a 
candidate gene in the pathogenesis of HIV AN, based on a high prevalence of DARC 
promoter polymorphisms in black patients; Liu et al ( 1999) have shown increased 
DARC expression in renal tissues from children with HIV AN and haemolytic uraemic 
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syndrome. However, conflicting results were reported by other investigators [Woolley 
et al, 2001]. 
1.5.6.4 Pathogenesis 
The pathogenesis and mechanisms involved in the rapid progression of IIlV AN are 
currently unknown. Until recently, how IIlV infection affected the kidney resulting in 
IDV AN was unclear. It may be a direct effect of IDV infection or an indirect renal 
response to IIlV-induced immune dysregulation. 
There has been conflicting data regarding the presence of IIlV-1 in renal cells in 
clinical HIV AN specimens. In 1989, Cohen et al reported the presence of HIV-I 
DNA in renal epitheHal cells by in situ hybridisation. Other investigators reported the 
finding of IDV-1 by polymerase chain reaction ( PCR) in glomerular cells, tubular 
cells, and infiltrating leucocytes in IIlV-infected patients with nephrotic range 
proteinuria [Ross el al., 2002; Kimmel el al.,1993]. However, other groups disputed 
the presence of JilV -I in renal parenchymal cells in JilV AN biopsy specimens 
[Barbiano et al., 1990; Eitner et al., 2000]. Further studies based on animals and 
humans shed more light onto the pathogenesis of HIV AN. 
Mice transgenic for a replication-defective IIlV-1 construct lacking the gag and pol 
genes, expressed under control of the viral promoter (long terminal repeat or LTR), 
develop proteinuria, renal failure, and histologic renal disease identical to JilV AN ( 
Dickie et al., 1991; Kopp et al., 1992]. Bruggeman et al (1997] later demonstrated 
that the HIV- I transgene is expressed in renal glomerular and tubular epithelial cells 
and that transgene expression in renal epithelial cells was required for the 
development of the JilV AN phenotype. 
Based on animal models, further attempts were made to determine whether HIV-I 
infects renal epithelial cells in HIV AN. Bruggeman et al (2000) reported a series of 
20 HIV-1-seropositive patients with renal disease who underwent renal biopsies. All 
but one of the patients were black or Hispanic, and 15 had HIV AN. In 11 of 15 
patients with HIV AN, HIV-I was detectable in renal epithelial cells by RNA in situ 
hybridisation. 
The mechanism by which HIV-1 gains entry into the renal epithelial cells is unknown. 
The receptor for HIV-I, CD4, and the major co-receptors for HIV-I, CCR5 and 
CXCR4 are not expressed in most normal renal epithelial cells. Some investigators 
have found CD4 and the major co-receptors in cultured renal epithelial cells [Conaldi 
et al., 1998]; however, no published studies have definitely demonstrated their 
expression in vivo [Eitner et al., 1998 & 2000]. Several other co-receptors for HIV-I 
have been recently identified [Clapham et al., 2002], however, whether they are 
expressed in renal epithelial cells remains to be determined. 
Renal biopsy examinations of patients with HIV AN have shown both proliferative 
and apoptotic changes. Renal tubular epithelial cells undergo rapid cell death and 
apoptosis in vitro after infection with HIV- l[Conaldi et al., 1998] The primary 
process is uncertain; however, because HIV AN kidneys are enlarged, proliferation is 
most likely the predominant process [Herman et al., 2003]. 
Transforming growth factor-f3 (TGF-P) is a fibrogenic cytokine that regulates human 
immune function and has been shown to regulate HIV replication [Lazdins et al., 
1991]. Increased deposition of matrix proteins and increased levels of TGF-f3 were 
found in kidneys with HIV AN compared with normal kidneys and with kidneys with 
32 
33 
thin basement membrane and minimal change nephropathies. This was also true when 
compared with kidneys of HIV-infected patients without HIV AN [Yamamoto et al., 
199.9]. 
Angiotensin II (AT II) has been shown to increase the cellular synthesis ofTGF-�. 
HIV proteases may interact with the renin-angiotensin cascade and serum angiotensin 
converting enzyme (ACE) levels have been found to be elevated in patients with HIV 
infection [ Ouellette et al., 1992]. 
Basic fibroblast growth factor (bFGF) has been linked to renal epithelial cell 
proliferation in some disease states. In a study comparing HIV transgenic mice with 
normal mice, transgenic kidneys bad increased bFGF and a greater number of bFGF 
binding sites. Transgenic tubular epithelial cells were found to express bFGF and 
transgenic epithelial cells or nontransgenic cells treated with bFGF exhibited an 
increased rate of proliferation compared with controls [Ray et al., 1994]. 
Infection of renal epithelial cells by HIV-I has important implications for HIV-I 
seropositive patients, not only because it contributes to renal disease but also because 
the kidney may be an important reservoir for HIV-l[Ross et al., 2002]. Bruggeman et 
al (2000) detected HIV- I in renal epithelial cells by both RNA in situ hybridisation 
and DNA in situ PCR in three patients with undetectable viral loads in peripheral 
blood. The quasi-species of HIV-1 present in renal epithelial cells clustered separately 
from sequences derived from the same patients' peripheral blood mononuclear cells. 
This indicates that HIV-I infection of tubular epithelial cells represents a viral 
compartment that is separate from the blood. Therefore, the renal tubular epithelium is 
a reservoir for actively replicating HIV-1 and may support evolution of viral strains 
that differ significantly from virus present in a patient's blood. It is unknown whether 
the renal epithelium is more likely to serve as a reservoir for drug-resistant IIlV-1 
strains or whether the renal epithelium is susceptible to currently available 
antiretroviral drugs. 
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Host factors appear to play an important role in the pathogenesis of IIlV AN. 
Bruggeman et al (2000) studied 7 seropositive individuals without lilV AN and 6 
were found to have renal cell infection by the presence of viral mRNA, DNA or both, 
suggesting that not all patients with renal infection manifest IIlV AN. Therefore, host 
factors must be important in rendering them vulnerable to developing IIlV AN. 
Several studies sug est strong genetic determinants ofIIlV AN as evidenced by the 
predominance of the disease in seropositive black patients. Freedman et al (1999) 
reported that patients with renal disease who are infected with IIlV were more than 
five times more likely to have relatives with renal disease than control patients 
without nephropathy. This data suggest an inherited susceptibility to renal disease 
among patients with IIlV AN. [Kimmel, 2003]. 
35 








Increased TGF-� synthesis 
/ 
Increased extracellular 
matrix production and 
decreased breakdown 
I � 
Glomerulosclerosis Interstitial fibrosis 
i � / 
Proteinuria Rapid loss of renal function 
[Humphreys MH, 1995] 
Renal cells 
Increased mv -1 replication 
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1.5.6.5 Clinical features 
HIV AN occurs almost exclusively in seropositive Black patients, with about 90% of 
patients being African-Americans. The remaining 10% of cases are observed in mixed 
heritage or Hispanic patients. This disorder is only very rarely found in seropositive 
White patients. Patients with HIV AN usually present with varying degrees of 
proteinuria , azotaemia and hypoalbuminaemia. They are typically normotensive. On 
renal sonogram, kidneys are echogenic and are normal or enlarged in size. Renal 
function may progress from relatively normal to end-stage renal disease requiring 
dialysis over a period of several weeks to months and most patients die within a year 
[Rao et al., 1987; Carbone et al., 1989; Ortiz et al., 1988). These characteristics are 
not generally found in other renal diseases in which glomerulosclerosis is seen, such 
as diabetic and heroin-associated nephropathy and idiopathic focal segmental 
glomerulosclerosis. 
1.5.6.6 Treatment 
HIV AN has become an important cause of renal failure and is the third leading cause 
of end stage renal disease in adult African-Americans in the United States
[USRDS,2001]. However, there have been no prospective randomised controlled 
studies with any form of therapy to date. Drugs that have been used in the treatment 
of HIV AN include corticosteroids, angiotensin converting enzyme (ACE) inhibitors 
and antiretroviral medications. 
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1.5.6.6.1 Corticosteroids 
Several uncontrolled studies were conducted to assess the benefit of corticosteroids in 
patients with lilV AN. Smith et al (1996) performed a prospective observational study 
in 20 patients with lilV AN who were treated with prednisone and were followed up 
for a median of 44 weeks. Most patients had advanced renal insufficiency and heavy 
proteinuria at the time of diagnosis. Seventeen patients experienced an improvement 
in renal function and reduction of proteinuria. However, several patients had relapses 
after steroid therapy. At the end of the first year, only two patients did not progress to 
ESRD. Six patients developed serious opportunistic infections. Altogether, 11 patients 
died during the study period. 
A recent retrospective study evaluated the outcome of steroid therapy in 21 patients 
with lilV AN and advanced renal failure, 13 of whom were treated with prednisone, 
compared with 8 patients who were not [ Eustace et al., 2000]. At 3 months, none of
the ,patients on prednisone had reached ESRD whereas 5 out of 8 patients who were 
not on prednisone had progressed to ESRD. By the end of l year, 8 patients in the 
treatment group were either dead or on dialysis, compared with 7 patients in the non­
treatment group. There was no difference in episodes of serious infections between 
the two groups after correcting for duration of follow up. However, there was an 
increased hospital stay in the steroid treated group. 
In conclusion, the role and efficacy of corticosteroids in lilV AN remains unclear. 
Further prospective randomised controlled studies are warranted . 
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1.5.6.6.2 ACE inhibitors ( ACEI) 
ACE! have been shown to be effective in reducing proteinuria and progression of 
renal disease in patients with diabetic and nondiabetic renal disease; therefore, they 
may produce similar results in patients with IIlV AN. In a retrospective case-control 
study, Kimmel et al (1996) reported an increase in renal survival associated with the 
use of Captopril in 18 patients with biopsy proven mv AN. Bums et al ( 1997) 
reported a prospective cohort study of 20 patients with IIlV AN and mild renal 
insufficiency. They were offered Fosinopril therapy however, 8 patients refused the 
treatment. All were followed up for 12 to 24 weeks. At the end of follow up period, 
those patients on Fosinopril had significantly lower levels of serum creatinine and 
proteinuria than those who were not on ACE! treatment. Seven patients in the study 
were on nucleoside reverse transcriptase inhibitor as a monotherapy. Wei et al (2003) 
performed a prospective study to determine the long-term effect of ACE! on renal 
survival in IIlV AN patients. Forty-four patients with mild renal insufficiency and 
biopsy-proven IIlV AN were included in the study. Twenty-eight patients received 
Fosinopril and 16 were followed as controls over the study period of 5.1 years. 
Median renal survival of treated patients was 479.5 days, with only one patient 
progressing to ESRD. All untreated patients developed ESRD with a significantly 
reduced median renal survival of 146.5 days. Although there are limitations, these 
studies suggest a role for ACE! in the management of patients with IIlV AN and 
further prospective studies are needed to determine the optimal role of ACEis in these 
patients. 
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1.5.6.6.3 Highly active aoti-retroviral therapy (HAART) 
Antiretroviral therapy was first used in a patient with HIV AN in 1989 who showed 
remission of his nephrotic syndrome for 11 months before relapse [Babut-Gay et al., 
1989]. Since then, various investigators have evaluated the use of antiretroviral 
medication for the treatment of HIV AN. Ifudu et al (1997) studied 23 HIV infected 
patients with proteinuria; 5 of them had biopsy proven HIV AN. All of them were 
treated with Zidovudine. Fifteen patients were compliant with treatment and none of 
them had worsening of renal function after a mean follow up of20.4 months. 
However, all 8 patients who were not compliant with Zidovudine treatment developed 
ESRD after a mean follow up period of 8 weeks. 
The effectiveness of ARV in HIV AN patients was also documented by other 
investigators as case reports. Winston et al (2001) and Wali et al (1998) both 
described a case report of patient with biopsy proven IIlV AN who had renal failure 
requiring haemodialysis support. They were treated with highly active antiretroviral 
therapy (HAART), and both of them improved dramatically, resulting in 
discontinuation of dialysis. Renal biopsies done before and after HAART showed the 
resolution of the histological features ofIIlV AN in both cases. 
Epidemiological studies also showed the effect ofHAART in patients with HIV AN. 
According to the USRDS data, the incidence ofESRD due to HIV AN has decreased 
among African-Americans with AIDS since the introduction ofHAART in 1996, 
although less rapidly than the incidence of death due to AIDS. Prospective, 
randomised studies evaluating the efficacy of HAAR T in preventing or delaying 
disease progression are warranted. 
1.5.6.6.4 Renal Replacement Therapy 
Although rates of HIV-related opportunistic infections and diseases decreased 
dramatically from 1995 to 1999, coincident with the introduction ofHAART (highly 
active antiretroviral therapy ), rates of HIV AN remains stable [Kaplan et al., 2000]. 
Without any treatment, HIV AN rapidly progresses to ESRD. Patients with ESRD 
require renal replacement therapy either in the form of haemodialysis, continuous 
ambulatory peritoneal dialysis (CAPO) or renal transplantation ultimately. A recent 
US Renal Data System (USRDS) database showed that 6, 179 patients with HIV 




The prevalence of HIV infection in various dialysis centres is variable and is 
dependent on the demographics of the population. In France, a much lower prevalence 
of0.36% was reported in a survey of260 dialysis facilities serving 22,707 patients 
[Poignet et al., 1999]. In an Italian survey of27,000 patients, a prevalence of0.13% 
was found (Barbiano di Belgiojoso et al., 1998]. 
During haemodialysis, various cytokines, such as IL-1, IL-6 and TNF-a, are released 
[Bingel et al., 1988; Herbelin et al., 1990; Varela et al., 2001]. These cytokines have 
been shown to increase viral replication in vitro (Osborn et al., 1989]. Therefore, 
HIV-infected patients on haemodialysis appears to be at a theoretical risk of increased 
morbidity. However, in the HAART era, Ahuja et al (2000) did a retrospective study 
involving 22 HIV-infected patients who were commenced on maintenance 
haemodialysis and they reported that survival of patients was much improved with the 
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use ofHAART versus less aggressive therapy ( one or two antiretroviral medications) 
. In this study, plasma viral load was also significantly lower in the patients who were 
on HAART therapy. Ahuja et al (2002) also showed an improved survival ofIDV­
infected patients on dialysis therapy in a later study. 
Data on the role of peritoneal dialysis in the treatment of IDV-infected patients with 
ESRD are limited. There have been suggestions by some investigators that increased 
protein losses with peritoneal dialysis in these patients may lead to increased 
morbidity and mortality [Tebben et al., 1993]. Ahuja et al (2002) recently compared 
survival among patients on haemodialysis and peritoneal dialysis in the United States 
by using the USRDS database and found no difference in survival between two 
groups, when adjusted for confounding variables. 
1.5.6.6.4.2 Transplantation 
Another form of renal replacement therapy is renal transplantation. Before the 
introduction ofHAART, an analysis of the USRDS showed that IDV-infected 
recipients were at increased risk of death and graft loss compared with uninfected 
recipients of cadaver kidneys [Swanson et al., 2002]. As the survival of IDV-infected 
patients has improved remarkably in the HAART era, renal transplantation as a form 
of renal replacement therapy is now being offered to IDV-infected patients with 
ESRD in some centres. Stock et al (2003) studies 14 IDV-infected patients who had 
kidney transplant (10 patients) and liver transplant (4 patients ). Patients were 
followed-up for means of 480 days and 380 days respectively. Rejection occured in 5 
of 10 kidney transplant recipients but did not occur in any of the four liver transplant 
recipients. There were no evidence of significant :mv progression and no adverse 
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effect of HIV on allograft function. Abbot et al (2004) from the United States recently 
did a retrospective study on 27,851 kidney transplant recipients with a valid HIV 
serology and found that 47 patients (0.2%) were HIV infected. All patients in the 
study were on HAART, had CD4 counts of more than 200, were free from 
opportunistic infections and had undetectable viral loads. It was found that HIV­
infected recipients had improved survival compared with HIV-uninfected recipients, 
although it was not statistically significant in the adjusted analysis. However, there 
were limitations in this study. It appears that healthier recipients were selected for 
transplantation; it was not possible to determine the use ofHAART therapy or to 
determine the clinical stage and other manifestations of disease in HIV-infected 
patients; none of the HIV-infected recipients had HIV AN and white patients were 
overrepresented. Although no broad consensus about improved posttransplantation 
survival for IDVmfected recipients in the modem era should be drawn from this 
study, it does appear that HIV-infected patients can enjoy successful outcome post­
transplantation. 
There are other factors that may favour posttransplantation survival as well. HIV­
infected recipients may benefit from many serendipitous effects of commonly used 
immunosuppressive agents. Sirolimus inhibits mv replication at the transcriptional 
level [Roy et al., 2002] and down-regulates the CCR5 receptor [Heredia et al., 2003]. 
Mycophenolate has inhibitory effects on HIV [Chapius et al., 2000],works 
synergistically with many antiretroviral agents [Margolis et al., 2002; Hossain et al., 
2002] and has been used to treat resistant strains of HIV [Press et al., 2002; Coull et 
al., 2001]. Certain calcineurin inhibitors such as cyclosporine has anti-HIV activity 
[Billich et al., 1995; Franke et al., 1996]. However, HAART therapy interacts with 
most immunosuppressive therapy, therefore careful monitoring and dose adjustment is 
crucial. In conclusion, the analysis of USRDS transplant population indicates that 
kidney transplantation in HIV-infected patients is plausible and ongoing. However, 
the proper use of immunosuppression and HAAR T therapy still awaits the results of 
properly designed prospective clinical trials. 
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CHAPTER2 
HYPOTHESIS AND OBJECTIVES 
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HYPOTHESIS AND OBJECTIVES 
As discussed in the earlier chapter, the impact of HIV infection in South Africa ranges 
from 16 to 20%, according to population-based and antenatal clinic surveys. This is 
equivalent to about 8.8 million infected people in South Africa. The true prevalence 
of renal diseases in the HIV infected population in Africa and South Africa is 
unknown as there is a paucity of data in this regard. If we consider the commonest 
form ofrenal involvement which is HIV AN, at least 10% of the infected population 
will have this disease. Therefore, about 880,000 South African will present with 
HIV AN during the course of HIV infection. The actual disease rate which has been 
mentioned in the initial studies, is likely to be higher than I 0%. If we take other renal 
involvement such as acute renal failure into consideration, the impact on renal 
services will be enormous. So it is important to look for the prevalence and pattern of 
renal involvement among the HIV-infected South African population. 
In any disease, it is desirable to get the diagnosis as early as possible. Early detection 
of the disease may be beneficial in evaluating early treatment which may help prevent 
the progression of the disease. This study, therefore, attempts to detect renal disease at 
an early stage among the HIV positive patients, in particular, HN AN. 
HIV AN is a disease which almost exclusively affects seropositive black patients. 
Without any treatment, renal function may progress from relatively normal to end­
stage renal disease requiring dialysis over a period of several weeks to months. 
Although there is no proven effective therapy currently available for such patients, 
ACE inhibitors have been depicted as an effective form of therapy in patients with 
various chronic renal diseases including idiopathic focal glomerulosclerosis which 
shares the same histopathological changes as HIV AN. Therefore, ACE inhibition 
might be beneficial in such patients. 
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The other objective of this study is to determine the efficacy of ACE inhibition in 
preventing renal disease progression in HIV-infected patients from an early stage of 
renal involvement. At the current time, due to the limited resources, HIV-infected 
patients are not considered for renal replacement therapy should they develop ESRD. 
Therefore, if ACEI can be proved to be beneficial in the early stage of HIV associated 
renal disease, these patients will benefit from such therapy which is financially 




3.1 Ethical app1-oval and patient consent 
Ethical approval was obtained from the University of KwaZulu-Natal Ethics 
Committee (Ref. Hl09/0l). The informed consent literature was available in both 
English and Zulu versions. Patients also received explanations regarding the 
following before the consent was obtained: 
• aims and objectives of the study
• study drug (Coversyl, an ACE inhibitor) and its possible side-effects
• blood and urine sample collections and
• kidney biopsy
3.2 Patient profile 
This is a single centre, prospective cohort study. Patients attending the HIV clinic at 
King Edward VIII hospital, referrals from Medical Out-Patient Departments and 
hospital in-patients were screened between April 2002 and April 2004. All the 
relevant demographic and clinical data were collected. 
3.2.J Inclusion criteria 
Inclusion criteria were: 
• HIV seropositivity
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( detection of HIV antibodies by ELISA test and confirmed by Western Blot)
• Proteinuria ranging from rnicroalbuminuria to overt/ macro-proteinuria
3.2.2 Exclusion criteria 
Patients with the following problems were excluded from the study: 
• Diabetes mellitus
• Uncontrolled hypertension (systolic blood pressure> l 80mmHg)
• Known causes of kidney diseases such as chronic pyelonephritis, autosomal
dominant polycystic kidney disease, systemic lupus erythematosus, etc.




Standard urine dipstick tests were done in all patients at the initial screening by using 
UriCheck 9 (RapiMed Diagnostics, Sekunjalo Health Care, Sandton, South Africa). 
Those with positive test for proteinuria proceeded to 24 hour urine collection to 
quantify the amount of protein in the urine which was done at the Chemistry 
laboratory, King Edward VIII Hospital, by using a timed endpoint method . Those 
\ov:ith negative dipstick tests who agreed to further screening underwent urine analysis 
for rnicroalburnin by using Micral-Test strips (Roche, Laval, Quebec, Canada). 
Patients with two positive tests for microalburnin at least a month apart were selected 
as having persistent microalburninuria and were asked to do 24 hour urine collection 
for quantification of microalbumin by the same timed endpoint method mentioned 
above. The confounding factors for rnicroalbuminuria such as fever, heavy exercise, 
cardiac failure, hyperglycaemia, uncontrolled hypertension, acute illness, urinary tract 
infection and prostatic disease had been looked for and were excluded. 
Based on the degree of proteinuria, patients were divided into 2 groups; those with 
urinary protein <l gm/24hour, including microalburninuric patients and those with 
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> 1 gm/24hour of urine protein. The former group was randomised according to the
randomization table and patients were either put on Perindopril (ACEI) or no 
treatment (Control). Initially 2 mg of Perindopril was used and then titrated 
subsequently to 4- 6mg/day as tolerated. All patients with > 1 gm/24hour of proteinuria 
were treated with Perindopril and were followed-up long term. 
Twenty-four hour urinary protein measurement was repeated after every 3 to 6 
months in all patients. Patients in this study were not on anti-retroviral therapy during 
the study period. None of them had used heroin or any illicit drugs in the past. 
3.3.2 Blood 
Blood samples were taken from the patients and processed by the Chemistry 
Laboratory (King Edward VIII hospital) for the following tests: 
• Urea and electrolytes (at entry to the study and three monthly thereafter ;serum
creatinine was measured by using a modified rate Jaffe· method)
• Blood glucose (random)
• CD4 count ( by Flow cytometry; at the entry and then 9 to 12 monthly )
• Antinuclear factor, Wasserman's reaction, Hepatitis B and C serology
3.3.3 Renal biopsy 
All patients who met the inclusion criteria underwent percutaneous renal biopsy under 
the ultrasound guidance, using a disposable trucut needle, after the biopsy site was 
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adequately anaesthetised with 2% lignocaine. All the kidney tissue samples were 
immediately immersed into the appropriate fixatives and were sent to the Anatomical 
Pathology Laboratory at the lnkosi Albert Luthuli Central Hospital. Light microscopy 
was done in all samples. The stains included Haematoxylin and Eosin, Periodic acid 
Shiff, methanamine silver, Jones and Masson's trichome. Nine cases had 
immunofluorescence (IMF) studies done for IgA, IgG, IgM,Complement C l q, C3 and 
C4. ( IMF studies were not done on 21 samples which were submitted at the initial 
part of the study. At that time, the Department of Anatomical Pathology made the 
ruling not to do IMF studies on samples from HIV-positive patients due to the 
possible hazards to the staff). Electron microscopy was performed in 6 patients ( not 
done in the others due to technical problems with the EM machine). All biopsy 
samples were examined by the staff at Anatomical Pathology Department, and 
thereafter reviewed by a single pathologist. 
3.3.4 GFR/Creatinine clearance 
In terms ofrenal function, GFR (glomerular filtration rate) was estimated by using the 
Modification of Diet in Renal Disease (MORD) equation and by calculating the 
creatinine clearance based on 24 hour urine samples and serum creatinine levels at 
study entry. Creatinine clearance was then calculated 3 monthly by using the MORD 
equation as follows: 
[Peterson et al., 1995) 
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3.4 Statistical Analysis 
Wilcoxon test was used for statistical analysis of paired data from the same patients at 
the entry and end of follow-up. Mann-Whitney U-test was used for statistical analysis 
of unpaired data between the patients of different groups. Probability values of less 
than 0.05 were considered significant. Survival function analysis was done by using 
Kaplan-Meier survival function estimates. The non-parametric Spearman r test was 
used to determine correlations. The interval-scaled variables ( initial and final levels 
of serum creatinine, Cr Cl and urine protein) of treated and control groups were 
compared using the Wilcoxon signed ranks test. To evaluate the effect of follow-up 
time, repeated measures ANOV A test was used which looked for the time effect on 





4.1 Demographics of study population 
A total of 615 patients were screened between April 2002 and September 2004. Six 
hundred and three (98%) of them were Black Africans, 9 (1.5 %) Indian, 2 (0.3%) White 
and 1(0.2 %) of mixed race origin There were 156 (25 %) males and 459 (75 %) females. 
Mean age was 27 (range 13 - 63 years). Fifteen of them (2.4 %) were in-patients and the 
remaining 600 (97.6 %) were out-patient�. Table 2 further defines the patient population 
Table 2. Characteristics of patients evaluated for proteinuria 
Characteristics Normoalbuminuric Microalbuminuric Macroalbuminuric 
UP0.03- (Protein uric) 
0.Jgm/24hours UP >0.3gm/24hours 
Demof!:raphics 
No. ofoatients 570 7 23 + (15#)
Age years mean(range) 27(13-63) 32(21-40) 32(17-55) 
Sex (M/F) 139/431(24.4% 2/5 (29% I 10/13 (43% I
175.6%) 71%) 57%) 
Race- Black 559(98%) 7(100%) 22(96%) 
- Indian 9(1.6%) 0 0 
- White 2(0.3%) 0 0 
- Mixed 0 0 I 
Clinical 
BP meanmmHg 117/70 121/81 120/74 
Peripheral oedema (%) 0 0 61 
Initial CD4 mean "163±34.6!! "216±32.7+ 264±46!!+ 
Initial urine protein Not done 0.14t 4.92t 
f!:m/24hours mean 
Initial serum creatinine 60 66. 125• 
µmoll/mean 
Initial Creatinine Not done 139! 77! 
Clearance ml/min mean 
HIVAN - 6(86%) 19(83%) 











Altogether, 30 patients were recruited for the biopsy arm of the study. There were 
variable follow-up periods ranging from 11 days to 667 days with a mean of304 days. 
4.2 Proteinuria 
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Thirty eight patients (6.0%) were found to have proteinuria ( proteinuria is defined as 
having 1 + or more of protein on standard urine dipstick testing). Fifteen of them (39 %) 
were in-patients and 23 ( 61 %) were out-patients .. Five patients refused renal biopsy, 
and 10 patients were lost to follow up before the biopsy was performed. Therefore, a total 
of 15 patients with proteinuria were excluded from the study. In total, 23 proteinuric 
patients (15 in-patients and 8 out-patients) underwent renal biopsy. Quantification of 
proteinuria revealed mean of 6 gm/24hour (range 0.47 - 24. 75) on study entry. 
Of the 30 patients, 11 had proteinuria of< I gm/24hour, whereas 19 patients had > 1 
• 
gm/24hour proteinuria at initial presentation. Tables 3 and 4 illustrate the characteristics 
of these patients. 
Table 3. Characteristics of patients with proteinuria < 1 gm/24hr 
Patient Age Gender Race CD4 Renal biopsy UP 
(!ID1/24hr) 
Controls 
1 28 F B 183 HIVAN 
2 40 F B 39 IN 
3 30 F B 239 IN 
4 ·21 F B 137 HIVAN 
5 40 M B 199 HIVAN+IN 
ACEI Group 
6 34 F B 611 IN 
7 29 F B 3 HIVAN 
8 26 F B 204 HIVAN+IN 
9 34 F B 246 HIVAN 
10 43 M B 114 HIV AN+Mem GN 
11 27 F B 370 HIVAN 
. .UP = Unne Protein; HIV AN = HIV -associated nephropathy; IN= Interstitial Nephritis 













Table 4. Characteristics of patients with proteinuria > lgm/24hr 
Patient Age Gender Race CD4 Renal biopsy 
ACEI Group 
1 25 M B 392 HIVAN 
2 30 F B 213 HIVAN 
3 29 M B 90 HIVAN 
4 42 M B 130 HIVAN 
5 29 F B 145 HIVAN 
6 • 24 F B 335 HIVAN 
7 55 M B 402 HIVAN 
8 32 F B 145 HIVAN 
9 26 F B - HIVAN 
10 26 M B 586 HIVAN 
11 39 M B - HIVAN 
12 21 F B 130 HIVAN 
13 42 M C 210 MPGN 
14 42 M B - HIVAN 
15 24 F B - HIVAN+Mem
GN 
16 29 M B 641 MPGN 
17 39 F B 159 HIVAN+Mem 
GN 
18 29 M B 331 HIVAN+Mem 
GN 
19 17 F B - HIVAN 
UP = Unne Protern ; Mem GN = Membranous Glomerulonephnhs 






















CD4 counts were not available in 5 patients because blood specimens did not reach the 
laboratory. All patients defaulted before another samples could be taken. From the 
<lgm/24hour proteinuric group, 6 were randomly put on Perindopril (ACEI) and 5 were 
followed up as a control group on no treatment. One patient from the treatment group 
(patient number 9, Table 3 and Table 5 ) lived at a great distance from the hospital and 
could not come regularly for her monthly medications. Therefore, she was excluded from 
further analysis in the study. At the end of follow-up, the ACEI-treated group showed 
stable proteinuria, whereas the control group revealed non-significant increase in 
proteinuria (p = 0.357 ) ( Figure 11 ). 
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Table 5. Outcomes of patients with proteinuria < lgm/24hr 
Patient Se Cr Cr Cl Follow Outcome Remark 
(µmol/1) UP(2It1/24hr) up 
Entry! Final Entl)j Fina Entrvl Final (days) 
Controls 
1 69 153 80 45 0.9 0.95 220 defaulted 
2 85 147 83 44 0.48 0.51 638 alive 
3 YI 43 229 191 0.13 0.10 561 defaulted 
4 61 74 139 110 0.07 0.08 542 defaulted 
5 111 120 82 75 0.23 0.94 560 alive also received 
Azathioprine for Alf 
ACEI ITTOUP 
6 73 71 102 105 0.47 0.38 367 Deceased Died from meningifo 
7 77 64 99 122 0.94 0.74 154 Deceased Died from PCP 
8 65 64 124 125 0.06 - 105 Deceased Died from PCP 
t9 62 88 123 82 0.30 0.78 498 defaulted stays far, treatment
intemmted 
10 70 77 138 116 0.04 0.02 667 alive 
11 58 47 140 177 0.17 0.13 323 alive 
texcluded from the study; Se Cr=Serum Creatinine; UP=Urine protein; AIH=Autoimmune Hepatitis; 
PCP=Pneumocystis carinii pneumonia 
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Table 6. Outcomes of patients with proteinuria > lgm/24hr 
Patien1 Se Cr P value Cr Cl P value UP(gm/24hr Pvalm Outcome 
(umol/1) 
entry end entry end entry end 
1 72 73 148 145 1.14 0.61 Defaulted 
2 156 147 43 47 1.35 - Died from PCP 
3 101 86 98 118 1.38 0.34 Alive 
4 80 80 118 118 2.23 1.39 Alive 
5. 172 1'70 39 40 4.47 - Died from PCP at 2' 12 
f6 112 573! 76 IO! 3.61 - Rx stopped after 1/12 
because of jK +, died from 
disseminated TB 
f value at time of death ( at 
3/12) 
7 103 97 84 90 4.92 1.27 Alive 
8 199 130 32 51 5.75 3.42 Died from CVA 
9 155 76 45 103 5.19 - Died from Pneumonia 
10 90 - 114 - 6.33 - Defaulted 
11 146 - 60 - 6.83 - Defaulted 
12 178 158 40 46 9.21 8.0 Defaulted 









*value on readmission 2/12
later on no Rx
213 160 38 53 11.64 10.0 Defaulted
63 56 130 149 11.15 8.5 Alive 
198 218 45 40 12.98 - Defaulted 
181 88 35 80 14.0 3.66 Defaulted 
78 52 132 208 24.75 0.83 Alive 
82 69 103 125 2.9 - Defaulted 
136 111.2 0.334 76.7 94.2 0.111 7.12 3.8 0.003 
t excluded from the study; PCP=Pnewnocystis carinii pneumonia; CVA=Cerebrovascular ac ident 
Patients 10 and 11 did not have final creatinines as they defaulted before the bloods were 
taken. All patients with proteinuria > 1 gm/24hour were treated with Perindopril. The anti­
proteinuric effect of ACEI was clearly seen among this group of patients with significant 
proteinuria Twenty-four hour urinary protein excretion significantly dropped from the 
base line value at the end of follow-up (p = 0. 003 ) (Figure 14 ). The degree of anti­
proteinuric effect was found to be correlated with the duration of follow-up as shown 
below. 
[change in urinary protein = -0.017 x follow-up time (days)+ 1.599] 
All patients who were treated with Perindopril tolerated the ACEI well except for one 
patient with HIV AN ( patient number 6, Table 6) from the >lgm/24hour urine 
proteinuria group developed hyperkalaemia and ACEI treatment was stopped after one 
month. Her renal function deteriorated and she died 2 months later with a diagnosis of 
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·disseminated tuberculosis. Serum creatinine at the time of death was 573 µmol/1. Another
patient from the same group with MPGN (patient numberl3,Table 6) defaulted
treatment after 2 months and was readmitted with severely deranged renal function
(Serum creatinine 520 µmol/1) 2 months after discontinuation of ACEI therapy. Both
patients were excluded from further analysis.
4.3 Microalbuminuria 
Microalbuminuria was tested in 90 patients who agreed to take part in the study. Thirty 
two patients (35.6%) had microalbuminuria; however, persistent microalbuminuria was 
found in only 7 patients (7.8%). All patients with persistent microalbuminuria agreed to 
participate further in the study. Altogether , 30 patients (23 with proteinuria and 7 with 
microalbuminuria) were recruited. Characteristics of patients with microalburninuria 









Table 7. Characteristics of patients with microalbuminuria 
Age Race Gender CD4 Se Cr Cr Clearance Hepatitis Urine Renal biopsy 
(yrs) creatinine Clearance (ml/min/1.73 serology protein 
(µmol/1) (ml/min) m2) (gm/24hr) 
[Measured] [Calculated] 
B C 
30 B F 239 37 188 188 - - 0.13 IN 
26 B F 204 65 63 123 - NA 0.06 HIVAN+IN 
34 B • F 246 62 95 123 - - 0.30 HIVAN 
40 B M 199 93 78 100 - - 0.23 HIVAN+IN 
43 B M 114 70 94 137 - - 0.04 HIVAN+Mem 
27 B F 379 68 104 116 - - 0.17 GN 
21 B F 137 61 130 138 - - 0.o7 HIVAN 
HIVAN 
. .  
IN=Interstitial Nephritis ; Mem GN=Membranous glomerulonephrit.Is ; NA= not available 
Table 2 compares the characteristics of all microalbuminuric and proteinuric patients. 
There were no statistically significant differences in mean age, mean blood pressure, 
initial mean CD4 count between the 2 groups except for the higher female to male ratio in 
microalbuminuric patients. Peripheral oedema was absent in all patients with 
microalbuminuria, whereas it was present in the majority (61 %) ofproteinuric patients. 
Initial 24 hour urinary protein and serum creatinine were significantly higher in the 
proteinuric group (p= 0.0138 and 0.0071 respectively). Initial Cr Cl was significantly 
lower in the proteinuric group (p= 0.0009). However, HIV AN was found to be equally 
present in both groups ( 86% and 83% ). 
4.4 CD4 count 
The mean CD4 count at the screening of all 615 patients was 196 (range 0-1088 )/mm3 . 
Patients with proteinuria had a mean CD4 count of 264 ( range 3 - 611 ) and those with 
persistent microalbuminuria had a mean CD4 count of 216 ( range 114 - 379 ); (Table 
2). Patients with nonnoalbuminuria had a mean CD4 count of 163 ( range 0 - 1088). 
Mean CD4 count of patients with HIV AN was 232 (range 3 - 586). 
4.5 Creatinine Clearance 
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- Creatinine clearance (Cr Cl) was both measured and calculated at entry to the study to
assess the correlation. Both correlated well in patients with any degree of proteinuria
(Correlation Coefficient= 0.802). Mean Cr Cl at entry was significantly lower in
proteinuric groups, compared to the microalbuminuric group (p = 0.0009) ( Table 2 ).
With ACEI therapy in patients with < 1 gm/24hour of proteinuria, there was non­
significant improvement in Cr Cl at the end of follow-up period (p=0.405), however, it
was significantly worsened in the controls group (p=0.042) (Figure 13). Cr Cl was better
preserved among the patients with > 1 gm/24hour of proteinuria who received ACEI,
although it was not statistically significant (p=0.111) ( Figure 16).
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Table 8. Characteristics of patients with proteinuria < lgm/24 hr by treatment group 
Characteristics Control ACEI Group *P value
(N=5) (N=5) 
Age (yrs) mean 31.8 31.8 1.0000 
Entrv CD4 mean 159 ± 34.2 260 ± 106.2 0.3920 
Final CD4 mean 104 ± 28.6 259± 90.7 0.1148 
*P value 0.1837 0.8760 
· Entry Se Cr '(µmol/1) 72.6 ± 12.3 68.6 ± 3.2 0.7826 
mean
Final Se Cr (µmol/1) 107.4 ± 21.2 64.6± 5 0.1314 
mean 
*P value 0.047 0.3327 
Entry Cr Cl 122.6 ± 28.8 120.6 ± 8.6 0.9455 
(rnllrnin)mean 
Final Cr Cl (ml/min) 93 ± 27.3 129 ± 12.4 0.2964 
mean 
*P value 0.042 0.405 
Entry UP(gm/24hr) 0.36 ± 0.15 0.34 ± 0.16 0.9118 
mean 
Final UP (gm/24hr) 0.52 ± 0.19 0.32 ± 0.15 0.6628 
mean 
*P value 0.3320 0.1182 
*Student t test
The effect of ACEI therapy in delaying disease progression was assessed by comparing 
the percentage of patients whose Cr Cl had halved at the end of the study. No patients 
from proteinuria of< lgrn/24 hr group on ACEI therapy had their Cr Cl halved, whereas 
I out of 5 (20%) patients from control group had this degree of declining renal function 
From the> lgm group, 2 out of 19 (10.5%) patients showed halving of Cr Cl ( Table 9). 
-
Table 9 . Percentage of patients with halving of creatinine clearance at the end of 
study ( proteinuria <lgm/24hour group vs >lgm/24hours) 
Proteinuria Creatinine clearance 
group halved 
no yes Total 
<1g Group ACEI Count 5 0 5 
% within 
100.0% .0% 100.0% 
Group 
Control Count 4 1 5 
% within 
80.0% 20.0% 100.0% 
Group 
Total Count 9 1 10 
% within 
90.0% 10.0% 100.0% 
Group 
>1g Group ACEI Count 17 2 19 
% within 
89.5% 10.5% 100.0% 
Group 
Total Count 17 2 19 
% within 
89.5% 10.5% 100.0% 
Group 
Kaplan-Meier survival function analysis (halving of Cr Cl ) was also performed in 
controls (5 patients) and the ACEI treated group(24 patients). More patients who had 
halved their Cr Cl were found in the control group which, however was not statistically 
significant ( p = 0. 7835). Similarly, a non-significant difference was found when 
comparing the 2 proteinuric groups (p = 0.6418) ( Figure 9 and Figure 10 ). 
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Figure 9. Kaplan-Meier survival functions ( halving of creatinine clearance ) in 
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Figure 10. Kaplan-Meier survival functions (halving of creatinine clearance) in 
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Patients with proteinuria < lgm/24hours (Continued) 







Figure 13. Change in mean creatinine clearance (entry and end of study] 
Patients with proteinuria > lgm/24hours 







Figure 14. Change in mean proteinuria with ACEI therapy 
[entry and end of study) 
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Patients with proteinuria > lgm/24hours 




entry Follow-up period end 
Figure 15. Change in mean serum creatioine with ACEI therapy 
(entry and end of study] 










Figure 16.Change in mean creatinine clearance with ACEI therapy 
[entry and end of study] 
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Figure 17. Variables of individual patients with proteinuria < lgm/24br 
(Controls vs ACEI therapy). Serial changes of serum creatinine, creatinine clearance (Cr Cl), 
and CD4 count ( y axis ), 24 hour urine protein (UP) ( secondary y axis) with or without ACEI 
treatment during the follow-up period ( months; x axis ) are shown for each patient ( controls were 
illustrated on the left column and treatment group on the right column for comparison ). 
Histological diagnoses are described at the bottom of each slide. ( MA = m.icroalbuminuria ) 











(1) Interstitial Nephritis (1) IDVAN 
(2)lllVAN (2) Interstitial Nephritis
(3) mv AN + Interstitial Nephritis (3) Interstitial Nephritis 
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(4)IDVAN (4) IBVAN
(5) lilV AN+ Interstitial Nephritis (5) IIlV AN+ Interstitial Nephritis
(6) IBVAN
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Figure 18. Variables of patients with proteinuria > lgm/24hr ( all on ACEI therapy) 
Serial changes of Serum creatinine, Cr Cl, CD4 counts and 24 hour urine protein (UP) 
during the follow-up period are shown for each patient. Histological diagnoses are 
mentioned at the bottom of each slide. 
[Units: Serum creatinine(µmol/1); Cr Cl(ml/min); CD4(/mm3); UP(gm/24hours)] 











HIVAN HIV AN+ Membranous GN 










HIV AN + Membranous ON Membranous ON 
Figure 19. All patients with proteinuria < 1 gm/24hr ( Control vs ACEI therapy) 
All patients from ACEI therapy group or Controls are shown. Serial changes of serum 
creatinine, Cr Cl, 24 hour urine protein and CD4 counts are plotted against the follow-up 
period. ACEI treated group (6 patients) are illustrated on the left and Controls (5 patients) 
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Figure 20. Patients with proteinuria > l gm/24hr 
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All 19 patients form this group were treated with ACEI. Serial changes of serum 
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4. 6 Histological types
Thirty patients with varying degree of proteinuria underwent renal biopsy. HIV AN was 
present in 25 (83 %) with a mean CD4 count of 232 ( range 3 - 586) (Table l0) (Figure 
22). Of25 patients, 6 (24%) had microalbuminuria. Altogether, 7 patients with 
microalbuminuria were biopsied and 6 (85 .7%) showed HJVAN with a mean CD4 count 
of 216 ( range l 37-379/mm3) (Table 7). Four patients with HIV AN had associated
membranous nephropathy (Table 11 ) (Figure 23 and 24). Two of them were hepatitis B 
serology positive. Other biopsy findings included 2 ( 7 % ) patients with 
membranoproliferative nephropathy and 3(10% ) with interstitial nephritis (Figure 21 ). 





j□ HIVAN ■ MPGN □ Interstitial Nephritis j
Total HIV AN = 25 (83%) 
HIV AN only = 21 (70%) 
HIV AN+ Membranous GN = 4 (13°/o) 
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Figure 22. Classical HN AN ( collapsing glomerulus) 
CollaPSine elomerulus 
Figure 23 (a). Membranous GN combined with HIV AN (collapsing glomerulus) 
Collapsine 2lomerulus 
Classic spike pattern of membranous elomerulopatltv 
Figure 23 (b) . High power view of Figure 23 (a) 
spikes 
Figure 23(c). Electron microscopy of Figure 23 (a) showing subepitbelial electron 
dense deposits 
[ subepithellal dePOSits 
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Table IO.Characteristics of patients with IIlVAN 
Patient Age Race Gender CD4 Se Cr Clearance Cr Cl Hepatitis Urine 
(yrs) creatinine (m.Vmin) (m.Vmio/ l .73m
2) Serology protein 
(µmol/1) [Measured] [Calculated] (gm/24hr) 
B C 
1 29 B F 3 77 88 99 (-) NA 0.94 
2 28 B F 183 103 80 71 (-) (-) 0.9 
3 26 B F 204 109 63 68 (-) NA 0.06 
4 34 B F 246 62 95 123 (-) (-) 0.30 
5 40 B M - 93 78 100 (-) (-) 0.23 
6 43 B M 114 70 91 137 (-) (-) 0.04 
7 27 B F 379 68 104 116 (-) (-) 0.17 
8 21 B F 137 61 130 138 (-) (-) 0.07 
9 26 B M 586 90 117 114 (-) NA 6.33 
10 17 B F - 82 48 102 (-) NA 2.9 
11 43 B M - 213 39 38 (-) (-) 11.64 
12 25 B M 392 72 138 148 (-) (-) 1.14 
13 24 B F 335 112 49 66 (-) NA 3.61 
14 38 B M - 161 55 54 (-) (-) 6.83 
15 21 B F 130 178 31 40 (-) (-) 9.21 
16 38 B F 159 181 45 35 (+) (-) 14.0 
17 29 B M 331 78 78 131 (+) (-) 24.75 
18 35 B M 402 103 89 92 (-) (-) 4.92 
19 32 B F - 135 50 51 (-) (-) 5.75 
20 29 B F 145 172 56 39 (-) (-) 4.47 
21 30 B F 213 156 22 43 (-) NA 1.35 
22 26 B F - 155 31 45 (-) NA 5.19 
23 42 B M 130 88 116 106 (-) (-) 2.23 
24 29 B M 90 119 104 89 (-) (-) 1.38 
25 24 B F - 63 97 129 (-) (-) 11.15 
B=Black ; M=Male ; F=Female ; NA=not available 
Table 11. Characteristics of patients with combined IDV AN and membranous 
nephropathy 
Patient Age Race Gender CD4 Se Cr Cr Cl Urine Hepatitis 
(yrs) (µmol/1) (ml/min) protein Serology 
[Measured) (gm/24hr) 
B C 
l 43 B M 114 70 94 0.04 (-) (-) 
2 38 B F 159 181 45 14.0 (+) (-) 
3 29 B M 331 78 78 24.75 (+) (-) 







Table 12. Characteristics of patients with non-IDV AN (other renal diseases) 
Patient Age Race Gender CD4 Serum Cr Clearance Hepatitis Urine 
(yrs) creatinine (ml/min) serology protein 
(µmol/1) [Measure/ (gm/24hr) 
Calculated) B C 
l 30 B F 239 37 188/188 (-) (-) 
2 29 B M 641 198 48/45 (-) (-) 
3 34 B F 611 73 135/102 (-) NA 
4 42 C M 210 147 25/58 (-) (-) 
5 40 B F 39 85 80/83 (-) (-) 
B=Black; C=Colored; IN=Interstitial Nephritis; MPGN=Membranoproliferative glomerulonephritis; 























The HIV-infected population is rapidly increasing in size. A human being is infected with 
HIV every 10 seconds on average (UNAIDS). In Africa, about 30 million people have HIV 
infection. Black patients have a relative risk of 51. l for developing end-stage renal disease 
(ESRD) from AIDS or AIDS-defining diagnosis compared with white patients [Barisoni L., 
2003]. In Africa, about 30 million people have lllV infection. However, the incidence of 
renal diseases associated with HIV infection in Africa is unknown. There is a paucity of 
published renal biopsy series from Africa. Pantanowitz et al (1999) reported renal biopsies 
of2I Black HIV-infected patients from Johannesburg, which showed FSGS in 62%; 
mesangial proliferative, membranous and post-infectious glomerulonephritis 14% each and 
mesangiocapillary glomerulonephritis in 5%. Eighty one percent of the biopsies showed 
tubulo-interstitial nephritis. Acute tubular necrosis was found in 48% of biopsies and 
pyelonephritis in 14%. Renal tuberculosis was present in one case. Diallo et al (1997) 
studied 33 HJV-infected Black African patients with nephrotic syndrome in Abidjan over a 
7 year period (1986-1993) and HIV associated nephropathy was found in 5(15%). Assounga 
et al ( l  996) performed a comparative study of HIV-positive versus HIV-negative patients 
from Congo, Brazzaville who presented with various renal problems. One hundred and 
seventeen patients were observed over one year period. A total of 43 (36.8%) were found to 
be HIV-positive; 32 of them underwent renal biopsy. Minimal change GN was found in 
25%; focal and segmental hyalinosis in 18.8%; MPGN in 18.8%; proliferative endocapillary 
GN in 3%; complex GN in 12.5%; Interstitial nephritis in 6.3%; amyloidosis in 6.3% and 
nephrosclerosis in 3%. 
The actual prevalence of HIV AN worldwide is uncertain. Available data were either based 
on renal biopsy or autopsy studies which gave variable results. Autopsy studies showed the 
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prevalence of HIV AN to be 1 to 12%, whereas a higher percentage was found in biopsy 
series. There are several renal biopsy series reported in the literature ( Table 13). 
Table 13. Renal biopsy series 
Study Country Number HIVAN Se Cr UP Mean Remark 
(biopsies) (%) (�1mol/l) (gm/24hr) CD4 
Bourgoignie . 176 146(83%) . . . Literature review of 
(Kl, 1990) biopsies reported 
before 1990 
Casanova ct al Italy 26 0 (0%) 61-735 0.2-17.6 . All white Italian 
(AmJKidney 
Dis, 1995) 
Connolly et al UK 19 11(58%) 137 • 1400 2.6-10.0 208 8 out of 11 patients 
( Q.JM, 1995) (<10- with 
630) HIV AN were Afro-
Carribean
Assounga ct al Congo 32 6(18.8%) . . . All black African 
(Saudi J Kidney 
Dis Transplant, 
19%) 
Praditpomsilpa Thailand 26 0 (0%) 53-2917 1.5-10.7 275 All Thai patients 
et al (<133 in92%) (11-560) 
(AmJKidney 
Dis, 1999) 
Winston ct al USA 20 10(50%) 123-495 I. I -12.0 60 9 out of 10 patients 
(Kl, 1999) (<133 in 10%) (0 -200) with HIVAN were 
African American 
Ahuja et al USA 14 9(64%) 59 332 All >1.5 187 All African American 
( AmJ <133 in 44%) (6 - 686) 
Nepltrol, 1999) 
Our study South Africa 30 25(83%) 61-213 0.04- 223 All South African 
(<133 in 68%) 24.75 (3 -586 )  black patients 
UP= unne protein; HIV AN=HIV-assoc1ated nephropathy 
Literature review by Bourgoigrue (1990) of renal biopsies in 176 HIV-infected patients 
reported before 1990 revealed focal segmental glomerulosclerosis in 83%. However, racial 
groups were not mentioned in the review, although it is likely that majority was black. In the 
later series, HIV AN was also found to be the commonest form of renal involvement in HIV­
infected black patients, ranging from 50% to 64%rconnolly et al, 1995; Winston et al, 
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1999; Ahuja et al, 1999]. In our study, 83% of patients had HIV AN which was higher than 
the later series. We screened both hospital in-patients as well as asymptomatic out-patients 
to cover different severity of disease. In terms of renal involvement, proteinuria is used as a 
marker. In our study, patients with variable degrees of proteinuria, ranging from 
rnicroalbuminuria to nephrotic range proteinuria, were screened and recruited. Therefore, 
this study covered both extremes of proteinuric patients from in- and out-patient groups. We 
screened a total of 615 patients; 15(2.4%) were in-patients and 600 (97.6%) were out­
patients; 38 (6%) had overt proteinuria and 7(7.8% of 90 patients tested) had persistent 
rnicroalbuminuria. 
HIV infection can affect the kidney and give rise to various forms of nephropathy. Among 
the various histological types we found in our study patients, it is interesting to note that 2 
different histological patterns i.e HIV AN and membranous nephropathy occurred 
simultaneously in 4 patients. Two of them were Hepatitis BsAg positive which could 
explain the membranous nephropathy. However, the other 2 had no explanation for this type 
of nephropathy. HbsAg was negative both by the rapid and ELISA tests done at the 
Virology laboratory. PCR for hepatitis B was not done. Although, in theory, PCR could be 
positive while HbsAg is negative, this is unlikely in a patient with a chronic infection. 
Therefore, both histological patterns may be directly related to HIV infection. The 
occurrence of two different histological patterns in the same patient simultaneously has 
never been reported in the literature. Characteristics of these patients with combined 
HIV AN and membranous nephropathy are shown in the Table 11. The heaviest degree of 
proteinuria was found in 3 (75%) of these patients.The presence of dual pathology, 
therefore, may be responsible for the massive proteinuria in these patients. 
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There are various subtypes of HIV- I; subtype B being the commonest in the United States, 
North America and Europe, whereas subtype C is accountable for the vast majority of 
infections in Africa [Quinn et al., 1998]. Casanova et al (1995) did a biopsy study in white 
Italian HIV-positive patients, however HIV AN was not demonstrated. Therefore, the HIV- I 
subtype may be one of the deterrninjng factors for the pattern of renal disease among the 
patients. However, the study done by Praditpornsilpa et al (1999) in Thailand, where 
subtype C is predommant as in sub-Saharan Africa, did not demonstrate a single case of 
HIV AN among 26 lllV-positive patients presenting with varying degrees of proteinuria. It 
is, therefore, possible that both race or genetic factors and HIV-I subtype may play a role in 
the development of HIV AN. 
The pathogenesis of HIV AN is unclear which makes recommendation of specific therapy 
difficult. Relentless progression of renal dysfunction in patients with HIV AN and lack of 
specific therapy for the disease leads to poor outcome in such patients. Corticosteroids, ACE 
inhibitors and anti-retroviral therapy have been used in small case series and in anecdotal 
reports; however, prospective randomised controlled studies are lacking. Some uncontrolled 
studies were done to determine the use of corticosteroids in HJV AN, but its efficacy and 
safety remain uncertairt Anti-retroviral therapy (ARV) has been recommended to improve 
renal functional abnormalities and outcome in patients with HIV infection [lfudu et al., 
1995; Wali et al., 1998; Dellow et al., 1999; Winston et al., 2001]. However, it has only 
recently been launched in government health services in South Africa and is not widely 
available to the majority of HIV-infected patients. Therefore, it is not current practice to use 
ARV in HIV associated renal disease. 
Prolonged renal survival with the use of ACE inhibitors has been well established in various 
proteinuric nephropathies [Ruggenenti et al., 1999; Taal et al., 2001; Chan et al., 2000; 
88 
Parving et al., 2001]. Based on these findings, ACEI becomes an option in managing 
patients with HIV AN. Wei et al (2003) recently showed the sustainable long-term 
renoprotective effect of ACEI in patients with lllV AN. Renal survival was significantly 
prolonged with ACE inhibition, independent of nephrotic status, anti-retroviral exposure. 
low CD4 count, or presence of moderate to severe chronic interstitial changes. The 
therapeutic effect of ACEI may be multifactorial [Kimmel et al., 1996]. Inhibition of ACE 
might affect HIV AN through renal haemodynamic changes or through the action at the 
molecular level, by down-regulating the expression of growth factors such as transforming 
growth factor-B (TGF-B), which plays a role in the pathogenesis of experimental 
glomerulosclerosis [Border et al., 1992 & 1994; Sharma et al., 1993]. It has antiproliferative 
effects, resulting in increased net e>..1racellular matrix synthesis and decreased degradation. 
Elevated plasma and tissue TGF-B levels have been reported in patients with AIDS [Kekow 
et al., 1990; Allen et al., I 991 l- TGF-B increases the expression of the lllV-1 L TR promoter 
in vitro in human mesangial cells [Shukla et al., 1993]. Renal cellular synthesis of TGF-B is 
increased by angiotensin II (AT II) [Hahn et al., 1991; Stouffer et al., 1992; Koibuchi et al., 
1993]. AT II has also been shown to stimulate another inflammatory modulator, NF-KB 
[Guijarro et al., 2001]. Therefore, it is possible that, by inhibiting ACE, ACEI decreases AT 
Il, thereby reducing renal tissue expression of TGF-B and NF-KB, resulting in delayed 
progression of the renal disease. Human immunodeficiency virus proteases may have 
activity in the rennin-angiotensin cascade and serum ACE levels have been found to be 
elevated in lllV-infected patients [Ouellete et al., 1992]. ACEis are protease inhibitors and 
this inhibition might have a salutary effect at the tissue level [Kimmel et al., 1996]. 
The anti-proteinuric effect of ACEI was clearly shown in patients with significant 
proteinuria (> lgm/24hour) in our study. However, this effect was not obvious in the group 
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with lower degrees of proteinuria (<lgm/24hour), although the amount of proteinuria was 
found to be stable at the end of the study. It is likely that the level of proteinuria was too 
small to be observed as a significant reduction. The anti-proteinuric effect of ACEI in this 
group, therefore, may be considered as a stabili:zation rather than reduction of proteinuria, 
which was evident in this particular group. Improvement in serum creatinine and Cr Cl in 
this group, although statistically non-significant, may be viewed as a renal protective effect 
of ACEI. These results did not reach significant level probably due to the small number of 
study patients. A longer duration of follow-up on larger group of patients is desirable to 
clarify these issues. The majority of patients in this group either defaulted or died from non­
renal causes, which limits our study. Regular attendence to the health services is a major 
problem in our patient population due to various socio-economic reasons. Increased 
mortality among the study patients from HIV-related diseases, yet with good renal function 
is the another major limitation to our study. In patients with significant proteinuria of 
>lgm/24hour, with ACEI therapy, Cr Cl was better preserved and the degree of anti­
proteinuric effect correlates with the duration of follow-up, suggesting that long term use of 
the drug may result in improved efficacy. The initial Cr Cl was found to be significantly 
lower in proteinuric patients compared with patients with microalbuminuria, showing 
inverse relationship of renal function and degree of proteinuria, supporting the well known 
nephrotoxic effect of proteinuria 
A salient feature of this study was the inclusion of patients with microalburninuria. Those 
patients with persistent microalbuminuira were selected to represent early, subclinical renal 
involvement in otherwise asymptomatic HIV-infected patients. Microalburninuria has been 
assessed by various investigators to diagnose subclinical renal involvement in systemic 
diseases. Valente et al ( 1998) performed renal biopsies in patients with systemic lupus 
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erythematosus who had microalbuminuria but without clinical signs of renal involvement, to 
evaluate subclinical lupus nephropathy. Fifteen patients (50%) had mesangial 
glomerulonephritis (MGN) type lib, 12 (40%) had MGN type Ila and 3 (I 0%) patients 
showed no changes on light microscopy or on immunofluorescence (type 1). Similarly, 
microalbuminuric diabetic patients were biopsied to detect the presence of diabetic 
nephropathy. Thirty four type 2 diabetic patients with microalbuminuria were biopsied by 
Fioretto et al (1996); 10 (29.4%) had typical diabetic nephropathy, 10 (29.4%) showed 
normal or near normal structure, 14 (41.2%) revealed atypical patterns of injury, with absent 
or only mild diabetic glomerular changes. Kanauchi et al (2001) also performed renal 
biopsies in 23 type 2 diabetic patients with microalbuminuria; 13 (57%) had typical diabetic 
glomerulosclerosis and 10 (43%) revealed atherosclerotic nephropathy without evidence of 
diabetic glomerulopathy. Studies were also done to detect an association between 
rnicroalbuminuria and hypertension [Parving et al., 197 4]. According to these findings, 
microalbuminuria appears to be an early indicator of renal disease in patients with systemic 
diseases. Therefore, microalbuminuria detected in HIV-positive patients may also indicate 
early (subclinical) HIV AN or may be a marker of non-HIV nephropathy. 
Luke et al ( l  992) measured rnicroalbuminuria in 72 HIV-seropositive ambulatory patients. 
There were 14 patients (19.4%) who had increased urinary microalbumin levels; 7 of these 
patients had nephrotic range proteinuria, similar to those values found in diabetic nephrotic 
syndrome. Two other studies showed the prevalence of rnicroalbuminuria in HIV-infected 
out-patients without clinical evidence of renal disease as 29.8% and 25% respectively 
[Kimmel et al., 1993; Kabandaetal., 1996]. However, renal biopsy was not performed in 
these patients to determine the pattern of renal pathology. To our knowledge, there are no 
renal biopsy studies done in HIV-infected patients with microalbuminuria to date. It was 
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considered that choosing those patients with rnicroalburninuria (which was persistent) would 
improve the detection of patients whose kidneys were silently affected and would rule out 
those with false positivity. In our study, 7 patients with rnicroalburninuria underwent renal 
biopsy and 6 (86%) patients showed HlVAN and 1(14%) had interstitial nephritis. 
Therefore, all patients were found to have histological abnormalities with almost all being 
discovered as having HlV AN, which is probably more than mere chance, although the small 
number may not allow statistically meaningful conclusions. Interestingly, the 
rnicroalburninuric group constituted 24% of all patients with histological evidence of 
HIV AN. However, these patients had good renal function [mean initial Cr Cl of 139 ml/min] 
and had low initial CD4 count lmean of 216]. Of the patients with HIV AN, the majority had 
low CD4 ( <250 in 12 out of 18 patients whose CD4 counts were available ), in keeping with 
other reports fWinston et al., 1998 & 1999]. It is, therefore, possible that HIV AN occurs in 
patients with low CD4 counts and can present initially with microalburninuria which has to 
be persistent. The beneficial effect of ACEJ in patients with rnicroalburninuria was unclear 
in our study; due to smal I numbers of patients, early mortality and non-compliance. Larger 
number of patients with a longer follow-up period is required to address this issue. 
When comparing the characteristics of patients who were evaluated for proteinuria, there 
were no significant differences in age, sex, race, and mean blood pressure among the 3 
different groups (Table 2). However, one unanticipated finding in our study was that the 
mean CD4 count was the lowest in normoalbuminuric patients compared to micro- and 
macro-proteinuric groups, although both latter groups also had low counts. The reason for 
this is unclear. It may be a reflection of advanced HIV infection generally in all patients 
seeking medical attention. However, subclinical renal involvement in the apparently 
normoalburninuric group is not excluded as the majority were not tested for 
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microalbummuria. As persistent microalbuminuria was found in 7.8% amongst those whom 
we tested, it is likely that more patients with microalbuminuria would have been detected, 
had they all been tested. Then, subsequent renal biopsy, if done, would have shown the renal 





The number of people living with HIV has been rising in most regions and South Africa still 
remains the worst affected region in the world. As the lllV-infected population grows, so 
will be the number of patients with varying degrees of renal involvement who ultimately 
will impose a threat on currently overburdened renal services in the region. Preventive 
measures still need to be re-enforced in an attempt to reduce the number of new cases. Care 
of the already-infected patients should be optimised, including provision of anti-retroviral 
therapy to a larger scale. Patients should be regularly screened for the presence of 
proteinuria. Those with overt proteinuria and renal impairment, should have histological 
diagnoses established at an early stage of the disease. ACEI therapy needs to be initiated as 
early as possible in patients with HIV AN and all proteinuric nephropathies in HIV-infected 
patients, which is the only promising therapy widely available to our patient population 
currently. HIV AN should be considered as an AIDS defining illness and ARV initiated. 
Microalbuminuria is a manifestation of HIV AN in our study patients. Most patients with 
HIV AN had low CD4 count (<250/mm3). Screening for microalbuminuria may be beneficial 
in HIV-infected patients with low CD4 count. Renal biopsy may be a consideration in those 
with persistent microalbuminuria, in order to diagnose HIV AN at an early stage and to 
achieve the maximal benefits of ACE inhibition. Further prospective randomised controlled 
trials with ACEI and ARV are needed. 
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